1	Copy-number variants as modulators of
2	common disease susceptibility
3	
4	Chiara Auwerx ^{1,2,3,4,*} , Maarja Jõeloo ^{5,6} , Marie C. Sadler ^{2,3,4} , Nicolò Tesio ¹ , Sven Ojavee ^{2,3} ,
5	Charlie J. Clark ¹ , Reedik Mägi ⁶ , Estonian Biobank Research Team ^{6,§} , Alexandre
6	Reymond ^{1,#,*} & Zoltán Kutalik ^{2,3,4,#,*}
7	
8	
9	¹ Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
10	² Department of Computational Biology, University of Lausanne, Lausanne, Switzerland
11	³ Swiss Institute of Bioinformatics, Lausanne, Switzerland
12	⁴ University Center for Primary Care and Public Health, Lausanne, Switzerland
13	⁵ Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
14	⁶ Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
15	§ Estonian Biobank Research Team: Tõnu Esko, Andres Metspalu, Lili Milani, Reedik Mägi, Mari Nelis
16 17	[#] These authors jointly supervised this work.
18	* Correspondence:
19	Chiara Auwerx: chiara.auwerx@unil.ch; Alexandre Reymond : alexandre.reymond@unil.ch; Zoltán

20 Kutalik: zoltan.kutalik@unil.ch.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 ABSTRACT

Background: Copy-number variations (CNVs) have been associated with rare and
 debilitating genomic syndromes but their impact on health later in life in the general population
 remains poorly described.

Methods: Assessing four modes of CNV action, we performed genome-wide association scans (GWASs) between the copy-number of CNV-proxy probes and 60 curated ICD-10 based clinical diagnoses in 331,522 unrelated white UK Biobank participants with replication in the Estonian Biobank.

29 **Results:** We identified 73 signals involving 40 diseases, all of which indicating that CNVs 30 increased disease risk and caused earlier onset. Even after correcting for these signals, a 31 higher CNV burden increased risk for 18 disorders, mainly through the number of deleted 32 genes, suggesting a polygenic CNV architecture. Number and identity of genes disturbed by CNVs affected their pathogenicity, with many associations being supported by colocalization 33 34 with both common and rare single nucleotide variant association signals. Dissection of 35 association signals provided insights into the epidemiology of known gene-disease pairs (e.g., 36 deletions in BRCA1 and LDLR increased risk for ovarian cancer and ischemic heart disease, 37 respectively), clarified dosage mechanisms of action (e.g., both increased and decreased 38 dosage of 17g12 impacts renal health), and identified putative causal genes (e.g., ABCC6 for 39 kidney stones). Characterization of the pleiotropic pathological consequences of recurrent 40 CNVs at 15g13, 16p13.11, 16p12.2, and 22g11.2 in adulthood indicated variable expressivity 41 of these regions and the involvement of multiple genes.

42 Conclusions: Our results shed light on the prominent role of CNVs in determining common
43 disease susceptibility within the general population and provide actionable insights allowing
44 to anticipate later-onset comorbidities in carriers of recurrent CNVs.

45

46 **KEYWORDS**

47 Structural variation; CNV; GWAS; common diseases; pleiotropy; genomic disorders.

48 BACKGROUND

49 Copy-number variants (CNVs) refer to duplicated or deleted DNA fragments (\geq 50bp) and 50 represent an important source of inter-individual variation [1,2]. As a highly diverse mutational 51 class, they can alter the copy-number of dosage sensitive genes, induce gain- or loss-of-52 function (LoF) through gene fusion or truncation, unmask recessive alleles, or disrupt 53 regulatory sequences, thereby representing potent phenotypic modifiers [3]. As such, their 54 role in human disease has mainly been studied in clinically ascertained cohorts often 55 presenting with congenital anomalies and/or severe neurological (e.g., developmental delay 56 and intellectual disability, epilepsy) or psychiatric (e.g., autism or schizophrenia) symptoms [4-7] and today, close to 100 genomic disorders (i.e., disease caused by genomic 57 58 rearrangements) have been described [8,9]. Despite their deleteriousness, some of these 59 CNVs flanked by repeats recurrently appear and remain at a low but stable frequency in the 60 population [10].

61

62 The emergence of large biobanks coupling genotype to phenotype data has fostered the study 63 of CNVs in the general population. Whole genome sequencing represents the best approach 64 to characterize the full human CNV landscape [1,11,12] but current long- and short-read sequencing association studies have limited samples size [13-15]. Alternatively, larger 65 66 sample sizes are available for exome sequencing data, offering the possibility to assess the 67 phenotypic consequence of small CNVs [16,17], while microarray-based CNV calls are bettersuited for the study of large CNVs and have been successfully used in association studies 68 69 [8,18-28]. Performing a CNV genome-wide association study (GWAS) on 57 medically 70 relevant continuous traits in the UK Biobank (UKBB) [29], we previously identified 131 71 independent associations, including allelic series wherein carriers of CNVs at loci previously 72 associated with rare Mendelian disorders exhibited subtle changes in disease-associated 73 phenotypes but lacked the corresponding clinical diagnosis [23]. Paralleling findings for point 74 mutations [30–33], this supports a model of variable expressivity, where CNVs can cause a

75 wide spectrum of phenotypic alteration ranging from severe, early-onset diseases to mild 76 subclinical symptoms, opening the question as to whether these loci are also associated with 77 common diseases.

78

79 Unlike continuous traits that can be objectively measured in all participants, population 80 cohorts, such as UKBB, have low numbers of diseased individuals [34]. Moreover, defining 81 cases relies on the arbitrary dichotomization of complex underlying pathophysiological 82 processes [35]. Beyond the inherent loss of power associated to usage of binary variables 83 [36], cases might be missed because an individual did not consult a physician, was 84 misdiagnosed due to atypical clinical presentation, or is in a prodromal disease phase. Studies 85 investigating CNV-disease associations in the general population have either focused on only 86 few diseases [27,37] or well-established recurrent CNVs [20,38,39]. Alternatively, high-87 throughput studies have assessed a broad range of continuous and binary traits 88 simultaneously [17,24,25] without any precautions to accommodate the aforementioned 89 challenges. To date, the largest disease CNV-GWAS meta-analyzed ~1,000,000 individuals 90 [8]. While boosting power through increased sample size, it comes at the cost of extensive 91 data harmonization, resulting in the exclusion of smaller CNVs (< 100kb) and broader disease 92 categories (e.g., "immune abnormality"). Moreover, as this study includes several clinical 93 cohorts, phenotypes are biased towards neuropsychiatric disorders (24/54 phenotypes) for 94 which the role of CNVs is well-established [4-7].

95

96 Using tailored CNV-GWAS models mimicking four mechanisms of CNV action and time-to-97 event analysis, we investigate the relationship between CNVs and 60 carefully defined 98 common diseases affecting a broad range of physiological systems in 331,522 unrelated white 99 UKBB participants. Extensively validating our results, we report associations according to 100 confidence tiers and take advantage of rich individual-level phenotypic data to demonstrate 101 the contribution of CNVs to the common disease burden in the general population.

4

102 METHODS

- 103 1. Study material
- 104 Discovery cohort: UK Biobank

The UK Biobank (UKBB) is composed of ~500,000 volunteers (54% females) from the general UK population for which microarray-based genotyping and extensive phenotyping data – including hospital based International Classification of Diseases, 10th Revision (ICD-10) codes (up to September 2021) and self-reported conditions – are available [29]. Participants signed a broad informed consent form and data were accessed through application #16389.

110

111 Replication cohort: Estonian Biobank

112 The Estonian Biobank (EstBB) is a population-based cohort of ~208,000 Estonian individuals 113 (65% females; data freeze 2022v01 [12/04/2022]) for which microarray-based genotyping data 114 and ICD-10 codes from crosslinking with national and hospital databases (up to end 2021) are 115 available [40]. The activities of the EstBB are regulated by the Human Genes Research Act, 116 which was adopted in 2000 specifically for the operations of the EstBB. Individual level data 117 analysis in the EstBB was carried out under ethical approval 1.1-12/624 from the Estonian 118 Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data 119 according to release application 3-10/GI/34668 [20/12/2022] from the EstBB. All participants 120 signed a broad informed consent form.

121

122 Other public resources

The PheCode Map 1.2 (beta) (<u>https://phewascatalog.org/phecodes_icd10</u>) was used for ICD-10 code classification [41]. Genomic regions were annotated with the NHGRI-EBI GWAS Catalog (<u>https://www.ebi.ac.uk/gwas/</u>; 24/11/2022) [42], and the Online Mendelian Inheritance in Man (OMIM; <u>https://www.omim.org/</u>; 27/07/2022) [43]. Recurrent CNV coordinates were retrieved from DECIPHER (<u>https://www.deciphergenomics.org/</u>) [9]. Unless specified otherwise, Neale UK Biobank single-nucleotide polymorphism (SNP)-GWASs summary

statistics were used (<u>http://www.nealelab.is/uk-biobank</u>). Allele frequencies and genomic constraint scores (<u>p</u>robability of <u>L</u>oF <u>I</u>ntolerance (pLI); <u>L</u>oF <u>O</u>bserved over <u>Expected Upper</u> bound <u>F</u>raction (LOEUF)) originate from the Genome Aggregation Database (GnomAD; <u>https://gnomad.broadinstitute.org/</u>) [44]; pHaplo and pTriplo scores from [8]. Tissue-specific gene expression was assessed in the Genotype-Tissue Expression project (GTEx; <u>https://gtexportal.org/home/</u>) [45].

135

136 Software versions

137 CNVs were called with PennCNV v1.0.5 [46] using PennCNV-Affy (27/08/2009) and filtered 138 based on a quality scoring pipeline [47]. Genetic analyses were conducted with PLINK v1.9 139 and v2.0 [48]. ANNOVAR (24/10/2019) was used to map genes to genetic regions [49]. The 140 UCSC Genome Browser was used to determine the human genome size (GRCh37/hg19) and 141 the LiftOver tool was used to lift over genomic coordinates [50]. Statistical analyses were 142 performed with R v3.6.1 and graphs were generated with R v4.1.3.

143

144 2. CNV association studies in the UK Biobank

145 Microarray-based CNV calling

146 UKBB genotype microarray data were acquired from two arrays with 95% probe overlap 147 (Applied Biosystems UK Biobank Axiom Array: 438,427 samples; Applied Biosystems UK BiLEVE Axiom Array by Affymetrix: 49,950 samples) [29] and used to call CNVs as previously 148 149 described [23]. Briefly, CNVs were called using standard PennCNV settings and samples on 150 genotyping plates with a mean CNV count per sample > 100 and samples with > 200 CNVs 151 or single CNV > 10 Mb were excluded. Remaining CNVs were attributed a probabilistic quality 152 score (QS) ranging from -1 (likely deletion) to 1 (likely duplication) [47]. High confidence CNVs, 153 stringently defined by |QS| > 0.5, were retained and encoded in chromosome-wide probe-bysample matrices (i.e., entries of 1, -1, or 0 indicate probes overlapping high confidence 154 155 duplication, deletion, or no/low quality CNV, respectively) [47], which were converted into three 156 PLINK binary file sets to accommodate association analysis according to four modes of CNV

action. Details about the CNV encoding and handling of chromosome X are provided in
Supplemental Note 1. Probe-level CNV frequency was calculated [23]. All results in this study
are based on the human genome reference build GRCh37/hg19.

160

161 Case-control definition and age-at-disease onset calculation

A pool of 331,522 unrelated white British UKBB participants (54% females) was considered after excluding retracted (up to August 2020), as well as related, high missingness and nonwhite British samples (*used.in.pca.calculation* = 0 and *in.white.British.ancestry.subset* = 0 in Sample-QC v2 file). CNV outliers (*Microarray-based CNV calling*) and individuals reporting blood malignancies (i.e., possibly harboring somatic CNVs; UKBB field #20001: 10047, 1048, 1050, 1051, 1052, 1053, 1055, 1056, 1056; #41270: ICD-10 codes mapping to PheCode exclusion range "*cancer of lymphatic and hematopoietic tissue*"), were further excluded.

169

170 Cases and controls were assigned for 60 ICD-10-based clinical diagnoses using diagnosis -171 ICD10 (#41270), cancer code, self-reported (#20001), and non-cancer illness code, self-172 reported (#20002) to build exclusion and inclusion lists. For each disease, we first defined all 173 331,522 individuals as controls. We excluded individuals with a self-reported or hospital 174 diagnosis of a broad set of conditions that include the disease of interest, as well as related 175 disorders/ICD-10 codes (e.g., other cancers or radio-/chemotherapy for breast cancer; mood or personality disorders for schizophrenia). We then re-introduce as cases individuals having 176 177 received a restricted range of ICD-10 codes matching our disease definition. For second level ICD-10 codes, all subcodes are considered, otherwise only the specified ones. The disease 178 179 burden was calculated as the number of diagnoses (out of the 60 assessed) an individual has 180 received. For male- (prostate cancer) and female- (menstruation disorders, endometriosis, breast cancer, ovarian cancer) specific diseases, downstream analyses were conducted 181 182 excluding individuals from the opposite sex.

183

Based on the *date at first in-patient diagnosis* – *ICD10* (#41280) and the individual's *month* (#52) and *year* (#34) *of birth* (birthday assumed on average to be the 15th), the age at diagnosis was calculated by subtracting the earliest diagnosis date for codes on the inclusion list from the birth date and converting it to years by dividing by 365.25 to account for leap years.

188

189 Probe and covariate selection

Relevant covariates and probes were pre-selected to fit tailored main CNV-GWAS models and 190 191 reduce computation time. For each disease, a logistic regression was fitted to explain disease 192 probability as a function of age (#21003), sex, genotyping array, and the 40 first principal 193 components (PCs). Nominally significantly associated covariates ($p \le 0.05$) were retained for 194 the main analysis. CNV-proxy probes with a CNV frequency $\geq 0.01\%$ were pruned at $r^2 > 1000$ 195 0.9999 in PLINK_{CNV} (--indep-pairwise 500 250 0.9999 PLINK v2.0) to group probes 196 at the core of CNV regions while retaining resolution at breakpoints (BPs), resulting in 18,725 197 probes. For each disease, 2-by-3 genotypic Fisher tests assessed dependence between 198 disease status and probe copy-number (rows: control versus case; columns: deletion versus 199 copy-neutral versus duplication; --model fisher PLINK v1.9; TEST column GENO). Probes 200 with $p \leq 0.001$ and a minimum of two disease cases among CNV, duplication, or deletion 201 carriers were retained for assessment through the mirror/U-shaped, duplication-only, or 202 deletion-only model, respectively.

203

204 Genome-wide significance threshold

Due to the recurrent nature of CNVs, the 18,725 probes retained after frequency filter and pruning remain highly correlated and are thus not independent. Accounting for all of them would result in an overly strict multiple testing correction. Using an established protocol [22,23,51], we estimated the number of effective tests performed to $N_{eff} = 6,633$, setting the genome-wide (GW) threshold for significance at p $\leq 0.05/6,633 = 7.5 \times 10^{-6}$. This threshold is of the same order of magnitude as what others have estimated for disease CNV-GWAS [8].

211

212 Main CNV-GWAS model

213 Association between disease risk and copy-number of CNV-proxy probes was assessed 214 through logistic regression with Firth fallback (--covar-variance-standardize --glm firth-fallback omit-ref no-x-sex hide-covar --ci 0.95 PLINK v2.0), using 215 216 disease- and model-specific probes and covariates (Probe and covariate selection). Four 217 association models were assessed: the mirror model assesses the additive effect of each 218 additional copy (PLINK_{CNV}); the U-shape model assesses a consistent effect of any deviation 219 from the copy neutral state (PLINK_{CNV}, using the hetonly option in glm PLINK v2.0); the 220 duplication-only model (PLINK_{DUP}) assesses the impact of a duplication while disregarding 221 deletions; the deletion-only model (PLINK_{DEL}) assesses the impact of a deletion while 222 disregarding duplications. Odds ratios (OR) and their 95% confidence interval (CI) were harmonized (A1 to "T"; Supplemental Note 1 – Table 1), i.e., $OR_{new} = \frac{1}{OR_{old}}$ and 223 $CI_{new} = e^{\log(OR_{new}) \pm 1.96 * SE_{\log(OR_{old})}}$, respectively. GW-significant associations (p ≤ 7.5 x 10⁻⁶; 224 Genome-wide significance threshold) were pruned at $r^2 > 0.8$ (--indep-pairwise 3000 225 500 0.8 PLINK v2.0), giving priority to probes with the strongest association signal by 226 inputting a scaled negative logarithm of association p-value as frequency (--read-freq 227 PLINK v2.0). For the U-shape model, pruning was performed using custom code by extracting 228 229 probes from PLINK_{CNV} and recoding them to match U-shape numerical encoding. Number of 230 independent signals per disease was determined by stepwise conditional analysis. Briefly, for 231 each disease and association model, the numerical CNV genotype of the lead probe was 232 included along selected covariates in the logistic regression model. This process was repeated 233 until no more GW-significant signal remained.

234

Due to its continuous nature, the disease burden CNV-GWAS was based on linear 235 236 regressions between copy-number of selected probes and the disease burden (--glm omit-237 ref no-x-sex hide-covar allow-covars PLINK v2.0), correcting for selected 238 covariates. Post-GWAS processing was performed as previously described [23].

239

240 CNV region definition and annotation

241 CNV region (CNVR) boundaries were defined by the most distant probe within \pm 3Mb and $r^2 \ge$ 242 0.5 of independent lead probes (--show-tags --tag-kb 3000 --tag-r2 0.5 PLINK 243 v1.9; U-shape model: custom code, as described previously for pruning). Signals from different models were merged when overlapping (\geq 1bp) and involving the same disease, with 244 245 CNVR boundaries defined as the maximal CNVR. Characteristics of the most significant 246 model (i.e., "best model") are reported. The "main model" indicates which CNV type mainly 247 drives the association, i.e., when associations were found through multiple models, priority 248 was given to either the duplication-only or deletion-only models, otherwise to the model 249 yielding the lowest p-value. CNVRs were annotated with hg19 HGNC and ENSEMBL gene names using annotate variation.pl from ANNOVAR (--geneanno). Number of genes 250 251 mapped to a CNVR was calculated and set to zero for CNVRs with REGION not equaling 252 "exonic". Resulting count was used as a predictor for pleiotropy (i.e., number of associations) 253 through linear regression.

254

255 Statistical confidence tiers

256 Following primary assessment through logistic regression (Main CNV-GWAS model), three statistical approaches were implemented to gauge robustness of the lead probe's association 257 258 signal. First, we assessed post hoc the p-value of 2-by-3 genotypic Fisher tests (Probe and covariate selection). Second, we transformed the binary disease status into a continuous 259 260 variable by computing the response residuals of the logistic regression of disease status on 261 disease-relevant covariates. This allowed the usage of linear regressions to estimate the effect 262 of the CNV genotype (encoded according to all significantly associated models in the primary 263 analysis) on disease risk. The model generating the lowest p-value for the CNV encoding is 264 reported. Third, time-to-event analysis was used to assess whether CNVs influence age-at-265 disease onset. Age at last healthy measurement was calculated as age-at-disease onset for

266 cases and date of last recorded diagnosis (30/09/2021) minus birth date converted to years 267 for controls (Case-control definition and age-at-disease onset calculation). Cox proportional-268 hazards (CoxPH) models were fitted including disease-relevant covariates and numerically 269 encoded CNV genotype for either of the four association models as predictors, using coxph() 270 function from the R survival package [52]. The model with the lowest CNV genotype p-271 value is reported. CNV-disease associations were classified in confidence tiers depending on 272 whether they were confirmed by 3 (tier 1), 2 (tier 2), or 1 (tier 3) of the above-described approaches at the arbitrary validation significance threshold of $p \le 1 \times 10^{-4}$. Validation 273 274 approaches not being suited for continuous variables - which do not suffer from the same 275 caveats as binary traits - all disease burden associations were classified as tier 1.

276

277 Literature-based supporting evidence

278 Using three literature-based approaches, we examined whether disease-associated CNVRs 279 had previously been linked to relevant phenotypes. First, we investigated the colocalization of 280 autosomal CNVRs with SNP-GWAS signals. GRCh38/hg38 lifted CNVR coordinates were inputted in the GWAS Catalog and associations ($p \le 1 \times 10^{-7}$) relevant to the investigated 281 282 disease (i.e., synonym, continuous proxy, or major risk factor) were identified through manual 283 curation. Second, we overlapped OMIM morbid genes (i.e., linked to an OMIM disorder; morbidmap.txt) with disease-associated CNVRs. Through manual curation, we flagged 284 285 OMIM genes associated to Mendelian disorders sharing clinical features with the common 286 disease associated through CNV-GWAS. Third, we examined if implicated CNVRs overlapped 287 regions at which CNVs were found to modulate continuous traits [23] or disease risk [20,25].

288

289 3. Replication in the Estonian Biobank

290 CNV calling and sample selection

Autosomal CNVs were called from Illumina Global Screening Array (GSA) genotype data for 193,844 individuals that survived general quality control and had matching genotype293 phenotype identifiers, matching inferred versus reported sex, a SNP-call rate \ge 98%, and were 294 included in the EstBB SNP imputation pipeline. CNV outliers and individuals with a reported 295 blood malignancy were excluded, as previously described. High confidence CNV calls (|QS| 296 > 0.5) of the 156,254 remaining individuals were encoded into three PLINK binary file sets, 297 following the procedure described for the UKBB (CNV association studies in the UK Biobank).

298

299 EstBB disease definition

Disease cases and disease burden were defined similarly than in the UKBB. To account for differences in recording practices between the countries, Z12 (routine preventive screens for cancer), and D22-23 (benign skin lesions) subcodes, were removed from the exclusion list of cancer traits as they were much more frequent than in the UKBB and strongly reduced the number of controls. Due to lack of matching data in the EstBB, no self-reported diseases and cancers were used as an exclusion criterion for disease definition.

306

307 EstBB replication analysis

308 Related individuals with available CNV calls were pruned (KING kinship coefficient > 0.0884), 309 prioritizing individuals whose disease status was least often missing, leaving 90,211 unrelated 310 samples for the replication study. Disease-relevant covariates were selected among sex, year 311 of birth, genotyping batch (1-11), and PC1-20. For each of the 73 UKBB signals, probes overlapping the CNVR and with an EstBB CNV, duplication, or deletion frequency $\geq 0.01\%$, 312 313 were retained, depending on whether the mirror/U-shape, duplication-only, or deletion-only 314 was the best UKBB model, respectively. Association studies were performed on remaining 315 probes using disease-specific covariates and the best UKBB model, following the previously 316 described procedure. Forty signals (55%) could not be assessed due to null/low CNV 317 frequency, failure of the regression to converge, absence of at least one case CNV carrier, or 318 because not mapping on the autosomes. For the remaining 33 signals, summary statistics of 319 the probe showing the strongest association within the CNVR were retained and p-values 320 were adjusted to account for directional concordance with UKBB effects by rewarding and

penalizing signals with matching and non-matching effect size signs, respectively. Specifically, 321 one-sided p-values were obtained as $p_{new} = \frac{p_{old}}{2}$ and $p_{new} = 1 - (\frac{p_{old}}{2})$ for 24 concordant and 322 9 non-concordant signals, respectively. Accounting for 33 testable signals, the replication 323 threshold for significance was set at $p \le 0.05/33 = 1.5 \times 10^{-3}$. One-sided binomial tests 324 325 (binom.test()) were used to assess enrichment of observed versus expected significant associations at various thresholds ($\alpha = 0.1$ to 0.005 by steps of 0.005), with the R function 326 327 arguments: x the number of observed signals at α , n the number of testable signals (i.e., 33), 328 and p the expected probability of signals meeting α (i.e., α).

329

330 4. CNV region constraint analysis

331 Evolutionary constraint of genes overlapping disease-associated CNVRs, i.e., "disease 332 genes" (CNV region definition and annotation), was assessed by comparing their pLI, LOEUF, 333 pHaplo, and pTriplo scores to the ones of "background genes". The latter were identified by 334 annotating ranges of one or multiple consecutive probes with CNV frequency $\geq 0.01\%$ with 335 ANNOVAR (hg19 HGNC gene names) and excluding disease genes. For pLi and LOEUF, all 336 disease genes were considered together. For pHaplo and pTriplo, two disease gene groups 337 were considered: genes overlapping CNVRs with at least one association through the 338 duplication-only model and genes overlapping CNVRs with at least one association through 339 the deletion-only model. As many CNVRs associated through both models, the analysis was 340 repeated considering genes overlapping CNVRs with at least one association through the 341 duplication-only and none through the deletion-only model and vice-versa. Comparison with 342 background genes was done through two-sided Wilcoxon rank-sum test.

343

344 5. Extended phenotypic assessment

To elaborate on specific associations, we made use of the rich phenotypic data available for UKBB participants, as detailed in Supplemental Note 2. For fine-mapping of association

347 signals, CNV carriers were divided in subgroups based on visual inspection of CNV
348 breakpoints and segmental duplications, as detailed in Supplemental Note 3.

349

350 CNV versus copy-neutral comparisons

Comparisons between groups of CNV carriers and copy-neutral individuals always exclude low quality CNV ($|QS| \le 0.5$) carriers altogether. For diseases, prevalence is estimated as $q = \frac{c}{n}$, with *c* and *n* are the number of cases and total number of individuals in a group, and $SE(q) = \sqrt{\frac{q*(1-q)}{n}}$. Differences in prevalence compared to copy-neutral individuals were assessed by two-sided Fisher test. For continuous traits, comparisons are based on two-sided t-tests.

357

358 6. CNV burden analyses

359 CNV burden association studies

360 In the UKBB, individual-level CNV, duplication, and deletion burden were calculated as the 361 number of Mb or genes affected by high-confidence (|QS| > 0.5) autosomal CNVs, 362 duplications, and deletions, respectively, as previously described [23]. Association between 363 burden values and the 60 diseases (logistic regression) or the disease burden (linear 364 regression), was assessed including disease-relevant covariates in the model. Accounting for 365 the 61 evaluated traits, significance was defined at $p \le 0.05/61 = 8.2 \times 10^{-4}$. We next corrected 366 burden values for CNV-GWAS signals. For each disease, CNVs, duplications, and deletions overlapping (≥ 1bp) a CNVR significantly associated with the disease of interest through CNV-367 368 GWAS were omitted from the CNV, duplication, and deletion burden calculations if the CNVR had been found to associate with the disease through the mirror/U-shape, duplication-only, or 369 370 deletion-only model, respectively. Association studies were repeated using corrected burden 371 values. Only the most significant burden types are reported in the text.

372

373 Relative importance of protein coding regions in mediating the burden's effect

374 The average genome-wide gene density (GD_{GW}) was estimated to 8.4 genes/Mb based on 375 26,289 genes (i.e., unique HGNC gene names in hg19 RefSeg, excluding microRNAs but 376 including genes of uncertain function (i.e., "LOC")) and a human genome length of 377 3,137,161,264 bp. If CNVs affecting the coding and non-coding DNA have similar effects, we 378 expect that the impact of 1Mb affected by CNVs to be equivalent to 8.4 genes being affected by CNVs. Hence, the association effect size of the CNV burden measured in Mb (β_{Mb}) is 379 expected to be 8.4-times larger than the one measured in number of affected genes (β_{gene}), 380 i.e., $\frac{\beta_{Mb}}{\beta_{gene}} = 8.4$. This hypothesis was tested independently for the deletion and duplication 381 burdens for traits with at least one significant uncorrected burden association (i.e., 20 diseases 382 + disease burden). Significant deviations from the expected ratio were assessed by t-statistic: 383

384
$$t = \frac{8.4 - \frac{\hat{\beta}_{Mb}}{\hat{\beta}_{gene}}}{\widetilde{SD}}$$

where $\hat{\beta}_{Mb}$ and $\hat{\beta}_{gene}$ are the estimated effects of the burden measured in Mb or number of genes impacted by CNVs, respectively, on the assessed trait. \widehat{SD} is the empirically observed standard deviation of the $\frac{\tilde{\beta}_{Mb}}{\tilde{\beta}_{gene}}$ ratio, estimated based on 10,000 simulations of $\tilde{\beta}_{Mb} \sim N(\hat{\beta}_{Mb})$, $\widehat{Var}(\hat{\beta}_{Mb})$ and $\tilde{\beta}_{gene} \sim N(\hat{\beta}_{gene}, \ \widehat{Var}(\hat{\beta}_{gene}))$. P-values were computed based on a two-sided one sample t-test and deemed significant at $p \le 0.05/21 = 2.4 \times 10^{-3}$. This analysis was repeated for the modified burden definitions not accounting for CNVs overlapping diseaseassociated CNVRs.


392

393 **RESULTS**

394 The spectrum of common diseases in the UK Biobank

To mitigate issues related to disease definition, we used a three-step approach to designate cases and controls in the UKBB (Figure 1A; top). Starting from 331,522 unrelated white British individuals, we defined cases based on a narrow list of hospital-based diagnoses (i.e., ICD-10 codes) and excluded self-reported cases, as well as self-reported and hospital diagnoses

399 of related conditions. Sixty disorders spanning 12 ICD-10 chapters were selected to cover a 400 wide range of physiological systems, favoring conditions with sufficiently large sample size 401 and a likely genetic basis (Figure 1B; Figure S1A; Table S1). Except for systemic lupus 402 erythematosus (N = 422) and polycystic kidney disease (N = 454), all diseases had over 500 403 cases. Nineteen diseases had a case count > 10,000, with osteoarthrosis (N = 62,175) and 404 essential hypertension (N = 97,860) being the most frequent. Seven diseases had a median 405 age of onset < 60 years, predominantly female reproductive disorders, autoimmune 406 conditions, and psychiatric disorders. Conversely, the nine diseases with a median age at 407 onset \geq 70 years were mainly degenerative disorders of the brain, eye, and kidney, overall 408 aligning align with epidemiological knowledge of the respective diseases.



409

410 Figure 1. Overview of the study

411 (A) Schematic representation of the analysis workflow. Trait definition: For each of the 60 investigated 412 diseases, unrelated white British UK Biobank participants were assigned as controls, individuals self-413 reporting or diagnosed with the disease of interest or a broader set of related conditions were excluded 414 and set as missing, and individuals with a hospital-based ICD-10 diagnosis of the condition of interest 415 were re-introduced as cases. Primary association study: Disease-specific relevant covariates were 416 selected. Probes were pre-filtered based on copy-number variant (CNV) frequency, required to 417 associate with the disease, and a minimum of two diseased carriers was required for the probe to be 418 carried forward. Disease- and model-specific covariates and probes were used to generate tailored 419 CNV genome-wide association studies (GWASs) based on Firth fallback logistic regression according 420 to a mirror, U-shape, duplication-only (i.e., considering only duplications), and deletion-only (i.e., 421 considering only deletions) models. Independent lead signals were identified through stepwise

422 conditional analysis and CNV regions were defined based on probe correlation and merged across 423 models. Validation: Statistical validation methods (i.e., Fisher test, residuals regression, and Cox 424 proportional hazards model (CoxPH)) were used to rank associations in confidence tiers. Literature 425 validation approaches leverage data from independent studies to corroborate that genetic perturbation 426 (i.e., single-nucleotide polymorphisms (SNP), rare variants from the OMIM database, and CNVs) in the 427 region are linked to the disease. Independent replication in the Estonian Biobank. (B) Age at onset for 428 the 60 assessed diseases, categorized based on ICD-10 chapters and colored according to case count. 429 Data are represented as boxplots; outliers are not shown.


430 Copy-number variant genome-wide association study

431 To assess whether disease susceptibility is modulated by CNVs, we performed CNV genomewide association studies (GWASs), i.e., test if the copy-number of selected probes influence 432 433 the probability to develop a disease or an individual's disease burden (i.e., number of 434 diagnoses among the 60 studied diseases) (see Methods; Figure 1A; middle). Briefly, 435 microarray-called CNVs for 331,522 unrelated white British individuals were transformed to 436 the probe level after quality-control [23]. As CNVs can act through different gene dosage 437 mechanisms, four association models were assessed: mirror and U-shape models consider 438 deletions and duplications simultaneously, assuming that they impact disease risk in opposite 439 or identical direction, respectively, while the CNV type-specific duplication- and deletion-only 440 models assess independently the effect of duplications and deletions, respectively. To reduce 441 the number and complexity of implemented logistic regressions, pre-processing steps 442 selected relevant covariates and probes for each disease and model combination, thereby 443 lowering computation time and decreasing the multiple testing burden (Figure S2; Table S2). 444 All summary statistics are available (Data Availability).

445

Stepwise conditional analysis narrowed GW significant associations ($p \le 7.5 \times 10^{-6}$; see 446 447 Methods for threshold calculation) to 40, 41, 21, and 38 independent signals for the mirror, Ushape, duplication-only, and deletion-only models, respectively. These were combined into 70 448 449 risk-increasing (i.e., no disease-protecting CNV) associations and 3 disease burden 450 associations (Figure 2; Table S3). Forty-five associations (45/73 = 62%) were supported at 451 GW significance by multiple models, the lowest p-value (i.e., "best model") being obtained through the mirror, deletion-only, U-shape, and duplication-only models for 24, 23, 21, and 5 452

453 of the signals, respectively. No association was detected at GW significance by both the 454 duplication-only and deletion-only models, so that each signal was attributed a "main model" 455 that indicates whether the association is primarily driven by duplications or deletions (see 456 Methods; Figure 2). The main model should be interpreted with caution as both deletions and 457 duplications might influence disease risk but only one CNV type-specific model might reach 458 GW significance (e.g., due to higher frequency). This is particularly relevant as 73% (33/45) 459 of disease-associated CNV regions (CNVRs) have a higher duplication than deletion 460 frequency (Figure 2A). Hence, 95% (20/21) of signals mainly driven by duplications were also 461 identified by the mirror/U-shape model(s) and contribution of deletions cannot be excluded.



462 Figure 2. CNV-disease association map

(A) Duplication and deletion frequencies ([%]; y-axis; break: //) of the lead probe for each unique and
 non-overlapping disease-associated CNV region (CNVR), labeled with corresponding cytogenic band
 (x-axis; 16p11.2 is split to distinguish the distal 220kb breakpoint BP2-3 and proximal 600kb BP4-5
 CNVRs; non-overlapping CNVRs on the same cytogenic band are numbered). If signals mapping to
 the same CNVR have different lead probes, the maximal frequency was plotted. (B) Associations

between CNVRs (x-axis) and diseases (y-axis) identified through CNV-GWAS. Color indicates the main
association model. Size and transparency reflect the statistical confidence tier. Black contours indicate
overlap with OMIM gene causing a disease with shared phenotypic features. Black crosses indicate
overlap with SNP-GWAS signal for a related trait. Grey shaded lines indicate CNVRs with continuous
trait associations [23]. N provides count for various features.

473 Validation of identified CNV-GWAS signals

474 Across the 45 CNVRs, CNV frequencies were low, ranging between 0.01% (our frequency 475 cutoff) and 0.36%, with 87% (39/45) of CNVRs having a frequency \leq 0.1% (Figure 2A). Consequently, associations rely on a low number of diseased CNV carriers and require 476 477 validation (see Methods; Figure 1A; bottom; Figure 2B; Table S3). We used three statistical 478 approaches to assess the robustness of CNV-diseases associations: i) Fisher test, ii) residual 479 regression, and iii) time-to-event analysis through CoxPH modeling. We replicated 28/70 480 (40%), 23/70 (33%), and 70/70 (100%) of the associations with the respective methods at the arbitrary validation threshold of $p \le 10^{-4}$. This allowed to stratify associations in confidence 481 482 tiers, with 17 signals replicating with all methods (tier 1), 20 with two (tier 2), and 36 only 483 through time-to-event analysis (tier 3). Importantly, time-to-event analysis showed that CNVs 484 always contributed to an earlier age of disease onset, in line with the paradigm that diseases 485 with a strong genetic etiology have earlier onset [53].


486

487 In parallel, we gathered literature evidence linking genetic variation at CNVRs with relevant phenotypes (Table S3). Forty-eight signals (48/73 = 64%) mapped to a CNVR harboring a 488 489 least one OMIM morbid gene and in 15 cases, the gene was linked to a Mendelian disorder 490 sharing phenotypic features with the associated common disease. For instance, association 491 between 4q35 CNVs and corneal conditions (chr4:186,687,554-187,182,384; OR_{U-shape} = 18.2; 95%-CI [5.2; 63.1]; p = 5.0 x 10^{-6}) encompasses *CYP4V2* [MIM: 608614], a gene associated 492 493 with autosomal recessive Bietti crystalline corneoretinal dystrophy [MIM: 210370], a disorder 494 that impairs vision and progresses to blindness by age 50-60 years [54]. We next assessed 495 whether SNPs overlapping disease-associated CNVRs were reported to associate with the 496 implicated disease or a biomarker thereof in the GWAS Catalog. This was the case for 28

497 (28/66 = 42%) autosomal signals, a similar proportion (38%) than for continuous trait CNV-498 GWAS [23]. For instance, distal 22q11.2 CNVs increased risk for disorders of mineral 499 metabolism (chr22:21,797,101-22,661,627; OR_{mirror} = 0.02; 95%-CI [0.006; 0.083]; p = 9.9 x 500 10⁻⁹) and overlapped heel bone mineral density SNP-GWASs signals, while 3q29 CNVs 501 increased Alzheimer's disease risk (chr3:196,953,177-197,331,898; OR_{U-shape} = 11.8; 95%-CI [4.0; 34.7]; $p = 6.6 \times 10^{-6}$) and overlapped with SNP-GWAS signal for PHF-tau levels, and 502 suggestive signals ($p < 5 \times 10^{-6}$) for frontotemporal dementia and cognitive decline in 503 504 Alzheimer's disease. Finally, 37 signals (37/73 = 51%) mapped to nine CNVRs previously 505 found to be associated with complex traits [23].

506

507 We also set out to replicate association signals in 90,211 unrelated EstBB individuals [40], 508 using similarly case definition than for the UKBB (see Methods; Figure S1B). Requesting at 509 least one diseased CNV carrier, 33 of 73 associations could be evaluated, among which four were strictly replicated ($p \le 0.05/33 = 1.5 \times 10^{-3}$) and five additional ones reached nominal 510 511 significance ($p \le 0.05$) (Table S3). Compared to what would be expected by chance, this corresponds to a 5.5-fold ($p_{binomial} = 2.5 \times 10^{-5}$) and 30.3-fold ($p_{binomial} = 6.6 \times 10^{-7}$) enrichment 512 for replication at $p \le 0.05$ and $p \le 5 \times 10^{-3}$, respectively (Figure 3A). Despite low power, these 513 514 results support validity of the primary UKBB association signals. Signals replicating at nominal 515 significance are detailed in Figure 3B. Many harbor SNP-GWAS signals for related 516 phenotypes (7/9), relevant morbid OMIM genes (4/9), or map to CNVRs previously associated 517 with similar diseases (6/7) or biomarkers (4/9). Among them, two are in the lowest UKBB confidence tier. 15q13 duplications were linked to increased risk for acute kidney injury (AKI; 518 chr15:30,946,160-31,881,106 | UKBB: OR_{dup} = 4.6; 95%-CI [2.5; 8.4]; p = 7.1 x 10⁻⁷ | EstBB: 519 520 $p = 2.4 \times 10^{-4}$). Homozygous mutations in *FAN1* [MIM: 613534], one of the five genes mapping 521 to this CNVR, have been linked to karyomegalic interstitial nephritis [MIM: 614817], a 522 progressive renal condition that leads to CKD [55]. The second example links CNVs affecting 523 exon 2 and intron 2-3 of PRKN ([MIM: 602544]) – a gene causing juvenile autosomal recessive 524 Parkinson's disease [MIM: 600116] - to sleep disorders such as insomnia and hypersomnia 525 (chr6:162,705,164-162,873,489 | UKBB: $OR_{mirror} = 0.12$; 95%-CI [0.05; 0.26]; p = 1.6 x 10⁻⁷ | 526 EstBB: p = 0.047). This finding is particularly relevant given the region's high CNV frequency 527 (0.22%) and the fact that sleep disturbances are among the earliest symptoms of Parkinson's 528 disease [56]. Follow-up studies should determine whether these individuals are more prone 529 to develop Parkinson's disease in the future.



	UKBB discovery						EstBB replication			Literature support			
	Disease	CNV Region	Model	OR	Ρ	Tier	OR	P _{one-side}	Case/ CNV	SNP- GWAS	OMIM genes	CNV association	
												Crawford 2019	Auwerx 2022
GW	CKD	17q12 (17:34,755,219-36,249,489)	U	6.5	5.9e-9	1	37	1.8e-7	3/16	\checkmark	HNF1B (RCAD)	renal failure (DUP; p = 3e-4)	creatinine; urea; cystatin C
	AKI	16p11.2 BP4-5 (16:29,596,230-30,208,637)	DEL	16	5.6e-20	1	40	2.0e-4	1/10	~		renal failure (DEL; p = 6e-5)	creatinine; cystatin C
replication	AKI	15q13.2-15q13.3 (15:30,946,160-31,881,106)	DUP	4.6	7.1e-7	3	12	2.4e-4	2/39	X	FAN1 (KIN)	×	•
	HTN	16p11.2 BP4-5 (16:29,596,230-30,208,637)	DEL	4.6	3.4e-7	2	6.6	1.1e-3	7/13	\checkmark		hypertension (DEL; p = 9e-6)	•
	asthma	15q13.2-15q13.3 (15:30,912,719-32,516,949)	MIR	0.17	1.2e-6	2	0.25	4.7e-3	6/35	\checkmark		asthma (DEL; p = 2e-4)	forced vital capacity
	HTN	16p13.11 (16:15,127,986-16,308,285)	U	1.5	5.5e-6	1	2.0	8.1e-3	29/77	\checkmark	ABCC6 (PXE)	hypertension (DUP; p = 2e-5)	•
p < 0.05	COPD	7q31.2-7q31.31 (7:117,399,981-119,333,169)	MIR	8.5	5.7e-7	2	5.1	0.030	2/16	\checkmark		not tested	×
	CKD	16p11.2 BP4-5 (16:29,596,230-30,208,637)	U	4.4	2.7e-8	1	8.4	0.034	1/13	\checkmark		renal failure (DEL; p = 6e-5)	creatinine; cystatin C
	sleep	6q26.3 (6:162,705,164-162,873,489)	MIR	0.12	1.6e-7	3	0.68	0.047	18/206	x	PRKN (PD)	not tested	x

530 Figure 3. Replication of CNV-disease associations in the Estonian Biobank

531 (A) Enrichment for signal replication (y-axis; 95% confidence interval as grey ribbon) at different levels 532 of significance (alpha; x-axis) in the Estonian Biobank (EstBB). Color and size indicate the p-value of 533 the enrichment (one-sided binomial test) and the number of observed associations, respectively. 534 Dashed red line indicates 1x enrichment, i.e., the number of observed associations matches the number 535 of expected ones. (B) Associations replicated at nominal significance in the EstBB, color-stratified 536 according to whether they meet the discovery genome-wide (GW; $p \le 7.5 \times 10^{-6}$; dark green), replication 537 $(p \le 1.5 \times 10^{-3})$; green), or nominal $(p \le 0.05)$; light green) significance threshold. Disease (CKD = chronic 538 kidney disease; AKI = acute kidney injury; HTN = hypertension; COPD = chronic obstructive lung 539 disease), cytogenic band and coordinates, best model (MIR = mirror; U = U-shape; DUP = duplication-540 only; DEL = deletion-only), odds ratio (OR), p-value (P) and statistical confidence tier are given for the 541 UK Biobank (UKBB) discovery analysis. OR, one-sided p-values, and number of cases among CNV 542 carriers are provided for the EstBB replication. Overlap with SNP-GWAS signals for a related trait ($\sqrt{-1}$ 543 yes; X = no) or a relevant OMIM gene (RCAD = renal cyst and diabetes; KIN = karyomegalic interstitial 544 nephritis; PXE = pseudoxanthoma elasticum; PD = Parkinson's disease) is indicated. Previous 545 association with diseases[20] (duplication (DUP) or deletion (DEL) was associated with indicated

disease; no association (X); some CNVRs were not tested) and continuous traits [23] (disease-relevant
biomarkers are specified; other traits (*); no association (X)) are listed.

548 Evidence provided by statistical, literature-based, or independent replication help prioritizing the most promising associations for follow-up studies and pinpoint plausible candidate genes. 549 550 We highlight several examples where deviations by one copy-number are linked to common 551 diseases sharing clinical features with rare Mendelian conditions caused by homozygous 552 perturbations of the same genetic region. This argues against a dichotomic view on dominant 553 versus recessive modes of inheritance and analogously to allelic series, suggest that 554 Mendelian and common diseases represent different ends of the phenotypic spectrum caused 555 by genetic variation at a given locus.

556

557 Global characterization of disease-associated CNV regions

558 We sought to identify global characteristics that distinguish disease-associated CNVRs (Table 559 S4). Number of protein-coding genes embedded in disease-associated CNVRs, hereafter 560 referred to as "disease genes", ranged from 0 to over 30 and generally correlated with the 561 number of encompassed probes ($\rho_{Pearson} = 0.50$; $p = 4.2 \times 10^{-4}$; Figure S3A). Exceptions include single-gene CNVRs overlapping known pathogenic genes captured thanks to high 562 probe coverage (e.g., BRCA1). While only seven CNVRs (16%) associated with multiple 563 564 diseases, propensity for pleiotropy depended on CNV length (+0.16 association/disease gene; 565 $p = 1.5 \times 10^{-5}$). Accordingly, CNVRs containing more than five genes were also more likely to 566 associate with continuous traits ($OR_{Fisher} = 53.2$; p = 8.5 x 10⁻⁶) [23]. One CNVR that stood out 567 is the 600kb 16p11.2 BP4-5 region (Figure 2B). Originally identified as a major risk factor for 568 autism, schizophrenia, developmental delay and intellectual disability, macro-/microcephaly, 569 epilepsy, and obesity [57–63], we previously found the region to associate with 26 continuous 570 complex traits [23]. Here, we show that 16p11.2 BP4-5 deletions increase the risk of 12 571 diseases - including both new and previously reported associations across multiple organ systems – as well as the disease burden (+3 diseases/deletion; $p = 1.2 \times 10^{-26}$), while the 572

573 region's duplication drove increased risk for psychiatric conditions (i.e., bipolar disorder, 574 schizophrenia, and depression), in line with previous findings [62].

575

576 Next, we assessed whether disease genes were under stronger evolutionary constraint (i.e., 577 less tolerant to mutations) than genes affected by CNVs at the same frequency but not 578 associated with any disease (i.e., "background genes"). Compared to background genes, the 231 disease genes had more constrained pLI ($p_{Wilcoxon} = 1.3 \times 10^{-4}$; Figure S3B) and LOEUF 579 $(p_{Wilcoxon} = 1.9 \times 10^{-7}; Figure S3C)$ scores, suggesting stronger intolerance to LoF mutations. 580 581 Splitting CNVRs depending on whether they have at least one association through either the 582 duplication-only or deletion-only model, we evaluated whether embedded disease genes were 583 sensitive to having less (i.e., haploinsufficiency; Figure S3D) or more (i.e., triplosensitivity; 584 Figure S3E) than two functional copies. No significant difference in pHaplo scores were observed but genes overlapping regions whose duplication ($p_{Wilcoxon} = 9.0 \times 10^{-19}$) and deletion 585 $(p_{Wilcoxon} = 1.0 \times 10^{-23})$ have been linked to diseases were more likely to be triplosensitive than 586 587 background genes. Similar trends were observed considering genes overlapping CNVRs 588 involved uniquely through the duplication-only and deletion-only models and not the other 589 CNV type-specific model (Figure S3F-G). Overall, our results indicate that a CNVR's 590 pathogenicity is determined both by the number and characteristics of affected genes.

591

592 New insights in known disease genes

593 Two out of 12 female BRCA1 deletion carriers were diagnosed with ovarian cancer (chr17:41,197,733-41,276,111; OR_{del} = 284.3; 95%-CI [24.6; 3290.8]; p = 6.1 x 10⁻⁶; Figure 594 4A). BRCA1 [MIM: 113705] is a tumor suppressor gene whose LoF represents a major genetic 595 596 risk factor for the development of hereditary breast and ovarian cancer (HBOC) [MIM: 604370] 597 [64]. Exploring the clinical records of the 12 deletion carriers, we found five diagnoses of breast cancer (a trait assessed by CNV-GWAS but that did not yield a GW-significant association), 598 599 one of endometrial cancer, and one of Fallopian tube cancer, so that eight carriers (67%) had 600 received a HBOC diagnosis (Figure 4B). Not only was prevalence of HBOC higher among *BRCA1* deletion carriers ($OR_{Fisher} = 31.0$; $p = 1.1 \times 10^{-6}$), but disease onset was earlier (HR = 17.0; $p = 1.3 \times 10^{-15}$; Figure 4C). Among the four carriers with no HBOC, two had received cancer prophylactic surgery, de facto reducing the penetrance of the deletion. Surgeries were likely carried out based on family history of HBOC, which was reported for 6 carriers (50%), suggesting that these deletions are inherited. We did not observe higher prevalence of other cancer types (Figure 4B).

607


608 High abundance of Alu repeats make the low-density lipoprotein (LDL) receptor (LDLR) [MIM: 609 606945] susceptible to CNVs [65]. We found that deletion of exon 2-6 increased risk for 610 ischemic heart disease (IHD; chr19:11,210,904-11,218,188; OR_{del} = 31.2; 95%-CI [7.1; 137.8]; $p = 5.6 \times 10^{-6}$), a condition present in 8 of 14 deletion carriers (Figure 4D). Heterozygous - and 611 612 less frequently homozygous - mutations in LDLR represent the main genetic etiology for 613 familial hypercholesterolemia [66], which is characterized by elevated LDL cholesterol and 614 predisposition for adverse cardiovascular outcomes [67]. Previously identified in clinical 615 studies of familial hypercholesterolemia [68], the CNVR implicated by our analysis specifically 616 encompasses the ligand-binding domain of LDLR [66]. Confirming widespread prevalence and 617 family history (43%) of cardiovascular diseases (Figure 4E), medical records of deletion carriers further revealed higher prevalence ($OR_{Fisher} = 11.6$; p = 7.9 x 10⁻⁵) and earlier onset 618 (HR = 5.8; $p = 1.4 \times 10^{-7}$; Figure 4F) of pure hypercholesterolemia (E78.0), a code included in 619 620 our lipidemia definition but that did not yield a signal pick-up by the CNV-GWAS. As we 621 previously did not find the CNVR to associate with standardized blood biochemistry LDL levels 622 [23], we hypothesized that the latter were lowered by hypolipidemic agents. Ten (71%) 623 deletion carriers were on statins and six (43%) were additionally using cholesterol absorption 624 inhibitors, while the remaining four did not receive a dyslipidemia or IHD diagnosis and 625 harbored smaller deletions (i.e., P12-14; Figure 4E). We concluded that drugs likely masked 626 genetically determined LDL levels, as shown by higher LDL levels in the first primary care measurement on record, measured prior to the standardized LDL measurement ($p_{t-test} = 0.03$; 627 628 Figure 4G). Despite this, the recommended target of \leq 1.8 mmol/L for high-risk individuals [69]

629 was never met. By recovering known gene-disease pairs typically studied in clinical cohorts,

630 we showcase how the rich phenotypic data from biobanks can generate insights into the

631 mechanisms, epidemiology, and comorbidities of these diseases, implicating CNVs as

632 important genetic risk factors.



633 Figure 4. Refining contribution of CNVs to gene-disease pairs

634 (A) Genomic coordinates of the 12 females (P1-12) carrying a BRCA1 deletion (CNVR delimited by 635 vertical dashed lines), colored according to ovarian cancer diagnosis. (B) Left: Cancer and related 636 family/personal diagnoses received by individuals in (A). Color indicates age at diagnosis. Right: Counts 637 per ICD-10 code. (C) Kaplan-Meier curve depicting the percentage, with 95% confidence interval, of 638 females free of female-specific cancers over time among copy-neutral and BRCA1 deletion carriers. 639 Hazard ratio (HR) and p-value for the BRCA1 deletion are given (CoxPH model). (D) Genomic 640 coordinates of the 14 individuals (P1-14) carrying an LDLR deletion (CNVR delimited by vertical dashed 641 lines), colored according to ischemic heart disease (IHD) diagnosis. (E) Left: Medical conditions and 642 family/personal diagnoses and medication received by $\geq 3 LDLR$ deletion carriers in (D), following 643 legend in (B). (F) Kaplan-Meier curve for pure hypercholesterolemia (E78.0) among copy-neutral and 644 LDLR deletion carriers, following legend as in (C). (G) Low density lipoprotein (LDL)-cholesterol levels 645 (y-axis) from primary care data (first available measurement) and blood biochemistry (average over 646 instances) for six deletion carriers in (D) with at least one antecedent primary care LDL-cholesterol 647 measurement, colored according to IHD diagnosis. P-value compares the two data sources (paired 648 one-sided t-test). Grey horizontal line represents median LDL-cholesterol value (from blood 649 biochemistry) in non-carriers. Light and darker green background represent recommended target 650 values for low (\leq 3 mmol/L) and high (\leq 1.8 mmol/L) risk individuals, respectively. (H) 17g12 association 651 landscape. Top: Negative logarithm of association p-values of CNVs (dark grey; CNVR delimited by 652 vertical dashed lines) and SNPs (orange) [70] with chronic kidney disease (CKD) and SNPs with 653 estimated glomerular filtration rate (eGFR; red) [71]. Lead SNPs are labeled. Red horizontal dashed 654 lines represent the genome-wide threshold for significance for CNV-GWAS ($p \le 7.5 \times 10^{-6}$) and SNP-655 GWAS ($p \le 5 \ge 10^{-8}$). Middle: Genomic coordinates of genes and DECIPHER CNV, with *HNF1B*, the putative causal gene in red. Segmental duplications are represented as a gray gradient proportional to 656 657 the degree of similarity. Bottom: Genomic coordinates of duplications (blue) and deletions (red) of UK 658 Biobank participants overlapping the region. (I) CKD prevalence (± standard error) according to 17q12 659 copy-number (CN). P-values compare deletion (CN = 1) and duplication (CN = 3) carriers to copy-660 neutral (CN = 2) individuals (two-sided Fisher test). Number of cases and samples sizes are indicated 661 (N = cases/sample size). (J) eGFR levels according to 17g12 CN, shown as boxplots; outliers are not 662 shown. P-values comparisons as in (I) (two-sided t-test). Grey horizontal line represents median eGFR 663 in non-carriers. Light and darker green background represent mildly decreased (60-90 ml/min/1.73m²) 664 and normal (\geq 90 ml/min/1.73m²) kidney function, respectively. (**K**) Kaplan-Meier curve for CKD among 665 17q12 deletion and duplication carriers, following legend as in (C).

666 Biomarker CNV associations tag pathophysiological processes

Integration of biomarker and disease CNV-GWAS signals can identify high-confidence, 667 clinically relevant associations. Heterozygous LoF of HNF1B [MIM: 189907] and 17q12 668 669 deletions cause renal cyst and diabetes (RCAD) [MIM: 137920], a severe disorder 670 characterized by renal abnormalities and maturity-onset diabetes by the young [72,73]. While 671 we previously showed that renal biomarkers were increased in duplication carriers [23], here, 672 we demonstrate that both 17q12 deletions and duplications increase CKD risk (chr17:34,755,219-36,249,489; OR_{U-shape} = 6.5; 95%-CI [3.4; 12.1]; p = 5.9 x 10⁻⁹; Figure 4H), 673 with a prevalence of 33.3% ($p_{t-test} = 0.026$) and 16.9% ($p_{t-test} = 6.8 \times 10^{-5}$) among deletion and 674

duplication carriers respectively, versus 4.4% in copy-neutral individuals (Figure 4I). Results replicated in the EstBB ($p = 1.8. \times 10^{-7}$; Figure 3B) and are supported by 20% of CNV carriers showing signs of kidney disease based on estimated glomerular filtration rate (eGFR < 60 ml/min/1.73m²), compared to 2.2% in copy-neutral individuals (Figure 4J). Importantly, both 17q12 deletion and duplication lower age of CKD onset (HR ≥ 4.6; p ≥ 1.3 × 10⁻⁷; Figure 4K), providing strong evidence of the deleterious consequences on kidney health of altered dosage of 17q12.

682

Similarly, the blood pressure-increasing 16p12.2 deletion (chr16:21,946,523-22,440,319) 683 [19,23] increased risk for hypertension (OR_{del} = 2.7; 95%-CI [1.9; 3.8]; $p = 1.3 \times 10^{-8}$) and 684 cardiac conduction disorders (OR_{del} = 3.3; 95%-CI [2.2; 4.9]; $p = 1.1 \times 10^{-8}$), suggesting a role 685 686 in cardiovascular health (Figure S4A-D). Primarily associated with developmental delay and intellectual disability [74,75] – proxied by decreased fluid intelligence (p_{t-test} = 8.7 x 10⁻⁵) and 687 income ($p_{t-test} = 1.4 \times 10^{-12}$) in the UKBB (Figure S4E-F) – cardiac malformations are reported 688 689 in ~38% of clinically ascertained cases [76]. Among 193 UKBB deletion carriers, two (1%) had 690 congenital insufficiency of the aortic valve (Q23.1), corresponding to a higher but not 691 significantly different prevalence of cardiovascular malformations (Q20-28) than in copy-692 neutral individuals ($OR_{Fisher} = 2.1$; p = 0.251). The deletion also associated with pneumonia 693 $(OR_{del} = 3.0; 95\%$ -Cl [1.9; 4.6]; p = 5.4 x 10⁻⁷), coinciding with associations with decreased 694 forced vital capacity [23] (Figure S4G-H) and peak expiratory flow [19], together demonstrating 695 the clinical relevance of CNV-biomarker associations.

- 696
- 697 Dissecting complex pleiotropic CNV regions

While some CNV signals converge onto the same underlying physiological processes, others tie apparently unrelated traits to the same genetic region, suggesting genuine pleiotropy. 16p13.11 harbors multiple, partially overlapping recurrent groups of CNVs allowing finemapping of signals to different subregions of the CNVR (Figure 5). Through different association models, the CNVR was linked to uncorrelated traits including epilepsy, kidney

- stones, hypertension, alkaline phosphatase (ALP), forced vital capacity, and age at
 menopause and menarche. We previously proposed *MARF1* as a candidate gene for the
 female reproductive phenotypes [23] and will focus here on the remaining traits.
 - Α С p = 3.2e-15% epilepsy prevalence cat3 8.2% 10% cat2 p = 0.272 p = 0.2965% <ABCC6 duplications (N = 654) cat1 1.5% 0.9% 0.5% CN = 1 cat 1-4 N = 7/85 CN = 3 CN = N = 294.454cat 5 N = 1/218 cat 1-4 N = 5/557 Ε Genes p = 1.9e-3prevalence 16% 9.2% DECIPHER 12% Segmental du similarity [%] ental dup ш p = 0.065 cat1 kidney stones 8% cat4 4.3% cat3 0.995 deletions (N = 355) 2.3% 4% 0.990 cat 1 0.985 I 0.980 CN = 1 CN = CN = 2 N = 281,662 CN = 3 В G cat 1-4 N = 7/76 N = 9/211N = 12/530SNP-GWAS threshold -log₁₀(P) 6 Epilepsy signals p = 0.55980% **CNV-GWAS** threshold Se 4 epilepsy (deletion-only p = 0.517 p = 1.8e-4 60% 2 epilepsy (SNP) 43.3% 38.8% E 37.4% 0 35.3% 40% D ion Kidney stones signals 45 -log₁₀(P) 209 Nuperter 40 35 10 5 kidney stones (deleti kidney stones (SNP) rs41278174 0% calcium levels (SNP) CN = 1 cat 1-4 N = 31/80 CN = CN = 3 CN = 2 N = 275,051 cat 5 N = 79/211 cat 1-4 N = 223/515 phosphate levels (SNP) 0 F I p = 8.2e-5 9.7e-3 Hypertension signals 180 -log₁₀(P) 6 [U/L] hypertension (U-shape) p=0.318 p=0.526 160 4 hypertension (SNP) 140 2 phosphatase systolic blood pressure (SNP) 120 Н 100 -log₁₀(P) 80 6 Alkaline phosphatase signals alkaline 60 4 2 alkaline phosphatase (mirror) 40 alkaline phosphatase (SNP) 0 20 14 5 15 15.5 16 16.5 17 17.5 18 18.5 CN = 1 CN = 2 CN = 3 cat 1/3/4 N = 314,718 cat 1/3/4 N = 38 N = 383 CN = 1CN = 3 cat 2 N = 51 cat 2 N = 214 chromosome 16 [Mb]

706 Figure 5. Dissection of complex pleiotropic patterns of recurrent CNVs at 16p13.11

707 (A) 16p13.11 genetic landscape. Coordinates of UK Biobank duplications (shades of blue; top) and 708 deletions (shades of red; bottom) overlapping the maximal CNV region (CNVR delimited by vertical 709 dashed lines) associated with epilepsy, kidney stones, hypertension, and alkaline phosphatase (ALP). 710 CNVs are divided and colored according to five categories (cat1-5) to reflect recurrent breakpoints, with 711 atypical CNVs in grey. Breakpoints reflect segmental duplications, represented with a grey gradient 712 proportional to the degree of similarity. Middle: genomic coordinates of genes and DECIPHER CNV. 713 Inset: Overlap between ABCC6's exonic structure and cat5 deletions. (B, D, F, H) Negative logarithm 714 of association p-values of CNVs with (B) epilepsy; (D) kidney stones; (F) hypertension; and (H) ALP 715 (dark grey; model in parenthesis; CNVR delimited by vertical dashed lines) and SNPs with (B) epilepsy 716 [77]; (D) kidney stones [78], calcium levels, and phosphate levels (y-axis; break: //); (F) essential 717 hypertension and systolic blood pressure [79]; and (H) ALP. Lead SNPs are labeled. Red horizontal 718 dashed lines represent genome-wide thresholds for significance for CNV-GWAS ($p \le 7.5 \times 10^{-6}$) and 719 SNP-GWAS ($p \le 5 \ge 10^{-8}$). (**C**, **E**, **G**) Prevalence (± standard error) of (**C**) epilepsy, (**E**) kidney stones, 720 and (G) hypertension according to 16p13.11 copy-number (CN) and CNV categories from (A). P-values 721 compare deletion (CN = 1) and duplication (CN = 3) carriers to copy-neutral (CN = 2) individuals (two-722 sided Fisher test). Number of cases and samples sizes are indicated (N = cases/sample size). (I) ALP 723 levels according to 16p13.11 CN and CNV category, shown as boxplots; outliers are not shown. P-

values compare deletion (CN = 1) and duplication (CN = 3) carriers to copy-neutral (CN = 2) individuals
 (two-sided t-test). Grey horizontal line represents median ALP value in non-carriers.

726 The 654 duplications and 355 deletions overlapping the maximal CNVR (chr16:15.070.916-727 16,353,166) were grouped into 5 categories (cat1-5) based on their breakpoints (Figure 5A; 728 Supplemental Note 3). Risk for epilepsy was increased in deletion carriers (chr16:15,122,801-16,353,166; OR_{del} = 6.2; 95%-Cl [2.8; 13.4]; $p = 4.4 \times 10^{-6}$; Figure 5B), with a prevalence of 729 730 8.3% among cat1-4 deletion carriers compared to less than 1.5% among copy-neutral and 731 duplication carriers (Figure 5C). Previously associated with epilepsy in clinical cohorts 732 [6,80,81], the region harbors NDE1 [MIM: 609449], a gene associated with autosomal 733 recessive lissencephaly [MIM: 614019] and microhydranencephaly [MIM: 605013] and whose 734 mutation has been linked to epilepsy [82,83]. Deletions also increased risk for kidney stones $(chr16:15,120,501-16,353,166; OR_{del} = 5.9; 95\%-CI [2.9; 11.9]; p = 7.3 \times 10^{-7})$, with the CNV-735 GWAS signal peaking close to a missense variant (rs41278174 G>A; Frequency_A: 2.1%) in 736 737 exon 23 of ABCC6 [MIM: 603234] associating with calcium and phosphate levels through 738 SNP-GWAS (Figure 5D). These signals coincide with the recurrent cat5 deletion that covers 739 29 probes spanning exons 23-29 from ABCC6 (Figure 5A). Kidney stones prevalence reaches 740 4.3% among cat5 deletion carriers, in-between estimates for larger cat1-4 deletion carriers 741 (9.3%) and copy-neutral individuals (2.3%) (Figure 5E). A wide range of variants affecting 742 ABCC6 have been identified and linked to the calcification disorder pseudoxanthoma 743 elasticum through recessive [MIM: 264800] - and more rarely dominant [MIM: 177850] -744 inheritance [84–87], with the Alu-mediated cat5 deletion representing one of the most frequent 745 variants [88,89]. ABCC6 is expressed in the kidney and recent estimates from clinical cohorts 746 suggested that kidney stones are an unrecognized (i.e., not used to establish clinical 747 diagnosis) but prevalent (11-40%) feature of pseudoxanthoma elasticum [90-92]. Our data 748 support kidney stones as a clinical outcome of ABCC6 disruption with partial gene deletions leading to lower penetrance than large 16p13.11 deletions. Unlike epilepsy and kidney stones, 749 750 both deletion (39.2%) and duplication (42%) carriers are at increased risk for hypertension $(chr16:15,127,986-16,308,285; OR_{U-shape} = 1.5; 95\%-CI [1.3; 1.8]; p = 5.5 \times 10^{-6}; Figure 5F),$ 751

752 compared to copy-neutral individuals (35.3%) (Figure 5G). The CNVR overlaps a SNP-GWAS 753 signal for systolic blood pressure mapping to MYH11 [MIM: 160745] (Figure 5F). Expressed 754 in arteries, MYH11 encodes for smooth muscle myosin heavy chains and has been linked to 755 dominant familial thoracic aortic aneurysm [MIM: 132900], for which hypertension represents 756 a leading risk factor. Increased prevalence (37.4%) of hypertension among cat5 deletions 757 implicates ABCC6, suggesting cis-epistasis for hypertension risk at 16p13.11. Consistent with 758 this model, ABCC6 plays a role in vascular calcification as the causal gene for generalized 759 arterial calcification of infancy [MIM: 614473] [93,94], typically diagnosed by hypertension in 760 newborns. Interestingly, the previously described mirror association with ALP (chr16:15,070,916-16,276,964; $\beta_{\text{mirror}} = 6.6 \text{ U/L}$; p = 3.5 x 10⁻⁷) peaks at the distal end of the 761 762 CNVR [23], nearby a suggestive SNP-GWAS signal for ALP levels (Figure 5H). Splitting ALP 763 levels by CNV category revealed that this mirroring effect is driven by individuals with cat2 deletion (mean = 76.4 U/L; p_{t-test} = 9.7 x 10⁻³) and duplication (mean = 92.9 U/L; p_{t-test} = 8.2 x 764 10⁻⁵), as other CNV carriers had ALP levels indistinguishable from those of copy-neutral 765 766 individuals (mean = 83.6 U/L) (Figure 5I). Hence, we propose the distal region of the CNVR 767 to harbor the critical region regulating ALP levels, even if no obvious candidate gene could be 768 identified through literature review.

769

770 The proximal 22g11.2 region, previously linked to DiGeorge [MIM: 188400] and velocardiofacial [MIM: 192430] syndromes, harbors four low-copy repeat (LCR; labeled A-to-771 772 D) [95]. Building on evidence of complex association patterns with this CNVR [38], we report 773 novel associations between CNVs spanning LCR A-D and IHD (chr22:19,024,651-21,463,545; OR_{U-shape} = 2.1; 95%-CI [1.6; 2.8]; $p = 1.5 \times 10^{-7}$), LCR B-D and aneurysm 774 775 $(chr22:20,708,685-21,460,008; OR_{del} = 41.8; 95\%-CI [10.0; 175.1]; p = 3.2 \times 10^{-7})$, and LCR 776 A-C and headaches (chr22:19,024,651-21,110,240; OR_{mirror} = 3.7; 95%-CI [2.1; 6.5]; p = 4.8 777 x 10⁻⁶) (Figure S5A; Supplemental Note 3). Based on 3 LCR B-D deletion carriers with 778 aneurysm, this corresponds to a 22-times higher prevalence than in copy-neutral individuals 779 (Figure S5B). Association with IHD is better powered, with a prevalence of 12%, 21%, 16%,

and 20% among copy-neutral individuals and carriers of LCR C-D, B-D, and A-D CNVs, respectively (Figure S5C). This suggests that IHD risk scales with the amount of affected genetic content, supporting the presence of genetic driver(s) and/or modifier(s) in the C-D interval, beyond the prime candidate *TBX1* [MIM: 602054] [95]. Collectively, our data indicates that altered 22q11.2 dosage can result in a spectrum of cardiovascular afflictions of various degrees of severity, ranging from well-described congenital malformation [95,96] to adultonset cardiovascular disorders.

787

15g13 deletions spanning BP4-5 [MIM: 612001] – and to a lesser extent duplications – have 788 789 been associated with neuropsychiatric and developmental conditions [97,98], with the nicotinic 790 acetylcholine receptor ion channel CHRNA7 being proposed as the driver gene based on the 791 presence of similar phenotypes in individuals with a smaller deletion (D-CHRNA7-BP5) only 792 affecting CHRNA7 [99] (Figure S6A). While BP4-5 duplication carriers showed higher 793 of AKI (EstBB-replicated: Figures 3B, S6B), hemorrhagic prevalence stroke 794 (chr15:30,912,719-31,982,408; OR_{U-shape} = 7.5; 95%-CI [3.2; 17.9]; p = 4.3 x 10⁻⁶; Figure S6C), 795 and anemia (chr15:30,912,719-31,094,479; OR_{dup} = 4.9; 95%-CI [2.5; 9.7]; p = 3.2 x 10⁻⁶; 796 Figure S6D), reminiscent of associations with pulse rate, mean corpuscular hemoglobin, and 797 red blood cell count [19,23], this was not the case for the ~10-times more numerous D-798 CHRNA7-BP5 duplication carriers. Replicating an association with asthma [20] $(chr15:30,912,719-32,516,949; OR_{mirror} = 0.17; 95\%-CI [0.08; 0.35]; p = 1.2 \times 10^{-6})$ which 799 800 parallels decreased forced vital capacity [23] and peak expiratory flow [19], this was the only 801 deletion-driven signal for which the CNVR encompassed the entire BP4-5 region. However, only BP4-5 (46.2%; $p_{t-test} = 1.8 \times 10^{-5}$) deletion carriers had higher asthma prevalence than 802 803 copy-neutral individuals (12.1%) (Figure S6E). Overall, the non-neurological disorders we 804 associate with 15q13 CNVs appear to specifically involve dosage of the genes within BP4-D-805 CHRNA7 and not CHRNA7.

806


807 Pathological consequences of an increased CNV burden

808 By assessing the global pathogenic impact of CNVs we can capture the effect of ultra-rare 809 variants (frequency $\leq 0.01\%$), as well as those whose effect is not strong enough to reach GW 810 significance under current settings. Individual-level autosomal CNV (duplication + deletion), 811 duplication, and deletion burdens were calculated as the number of Mb or genes affected by 812 the considered type of variation and their predictive value on the same 60 diseases (and the 813 disease burden) previously assessed through CNV-GWAS was estimated (Figure 6A; left). Disease burden strongly associated with a high CNV load (Mb: β_{CNV} = +0.08 disease/Mb; p = 814 3.7 x 10^{-27} | Gene: β_{del} = +0.03 disease/gene; p = 3.7 x 10^{-27}) and risk for 20 individual disorders 815 816 was increased by at least one type of CNV burden ($p \le 0.05/61 = 8.2 \times 10^{-4}$; Figure 6B; left; 817 Table S5). Strongest effect sizes were observed for the Mb burden for psychiatric disorders, 818 such as bipolar disorder ($OR_{del} = 1.4$; p = 6.9 x 10⁻⁴), schizophrenia ($OR_{del} = 1.4$; p = 4.1 x 10⁻¹ ⁵), or epilepsy (OR_{CNV} = 1.1; $p = 8.3 \times 10^{-5}$), in agreement with CNVs representing important 819 risk factors for these complex and polygenic disorders. To ensure that we do not merely 820 821 capture the effect of individual CNV-disease associations previously isolated by CNV-GWAS, 822 we excluded CNVs overlapping disease-associated CNVRs from the burden calculation and 823 re-estimated their predictive value (Figure 6A; right). Overall association strength dropped but 824 signal was lost only for type 1 diabetes and chronic obstructive pulmonary disease (Figure 6B; 825 right; Table S5), suggesting that CNVs not captured by the CNV-GWAS contribute to 826 modulating disease risk. Establishing the polygenic CNV architecture of a substantial number 827 of common diseases, this implies that increased power will likely lead to the discovery of 828 further CNV-disease associations.

829

As the "gene burden" captures more associations than the "Mb burden" and as the deletion burden yields stronger associations than the duplication one (Figure 6B), we hypothesized that the pathogenic effect of CNVs is mainly driven by the number of deleted genes. Based on an average GW gene density of 8.4 genes/Mb, we assume the deletion burden measured in Mb (β_{Mb}) to be 8.4 times larger than the one measured in number of affected genes (β_{aene}),

835 expecting a ratio of 8.4 if the type of affected genetic content does not impact disease risk (see Methods; Figure 6C). Ratios significantly ($p \le 0.05/21 = 2.4 \ge 10^{-3}$) smaller or larger than 836 837 8.4 indicate disproportionately large or small contribution of protein coding regions, 838 respectively. We detected a larger than expected contribution of deleted genes to the disease 839 burden (ratio = 4.4; p = 1.3×10^{-6}), and AKI (ratio = 3.5; p = 7.0×10^{-4}) and lipidemia (ratio = 2.7; $p = 1.4 \times 10^{-3}$) risk, along with seven additional nominally decreased ratios (Figure 6D; 840 841 left; Table S6), confirming that haploinsufficient genes mediate the burden's effect on disease 842 risk. Repeating the analysis with the duplication burden did not reveal any significant deviations (Table S6). After correcting for CNV-GWAS signals, only AKI ($p = 7.0 \times 10^{-4}$), 843 844 arthrosis (p = 0.030), and disease burden (p = 0.016) showed increased contribution of deleted 845 genes on disease risk, indicating that a substantial fraction of effects capture by the CNV-846 GWAS are mediated by deletion of coding regions.



847 Figure 6. The coding deletion burden increases overall disease risk

848 (A) Burden calculation. Left: Raw CNV burden is calculated by summing up the length (in Mb or number 849 of affected genes) of all CNVs in an individual. Burden values are used as a predictor for disease risk. 850 Right: Corrected CNV burden is calculated by summing up the length of all CNVs that do not overlap 851 with a CNV region (CNVR) significantly associated with the investigated disease through CNV-GWAS. 852 Corrected burden values are used to re-estimate contribution of the CNV burden to disease risk (red 853 curve). (B) Contribution of raw and corrected CNV burdens in Mb or affected genes (x-axis) to disease 854 risk (y-axis). Only the most significantly associated burden, providing $p \le 0.05/61 = 8.2 \times 10^{-4}$, is shown. 855 Color indicates whether the CNV (duplication + deletion), duplication, or deletion burden was most 856 significantly associated, with size and transparency being proportional to the effect size (beta) and p-857 value, respectively. Grey horizontal bands mark traits with no CNV-GWAS signal. (C) Top: Based on 858 an average genome-wide gene density of 8.4 genes/Mb, we expect the effect of the CNV burden in Mb 859 to be 8.4x larger than the one measured in number of affected genes. Bottom: If the ratio is smaller 860 than 8.4, it indicates an increased contribution of coding regions. Alternatively, if larger than 8.4, it 861 indicates a decreased contribution of coding regions. (D) Ratio, with 95% confidence interval (CI), of 862 the raw and corrected Mb/genes deletion burdens (x-axis) for all diseases showing at least one 863 significant burden association. Significant deviation from the expected ratio of 8.4 (grey vertical line) is 864 indicated as *** for $p \le 0.05/21 = 2.4e-3$ and * for $p \le 0.05$ (two-sided one sample t-test). 865

DISCUSSION 866

867 Using an adapted GWAS framework, we provide a detailed investigation of the contribution of 868 CNVs to the genetic architecture of 60 common diseases and showcase how the rich 869 phenotypic data of the UKBB can be leveraged to gain new biological insights, highlighting the 870 role of CNVs as modulators of common disease susceptibility in the general population.

871

872 Various strategies have been used to study CNV-disease associations in the UKBB. Focusing 873 on diseases related to the ones assessed in the current study, we replicate 10 out of the 24 874 detected associations (at FDR \leq 0.1) with 54 likely pathogenic CNVs [20] and all four 875 associations (at $p \le 1 \ge 10^{-9}$) in a recent CNV-GWAS investigating 757 diseases [25]. Despite 876 analyzing the same dataset, we often obtained p-values orders of magnitude smaller (e.g., 16p11.2 BP4-5 deletion and AKI: $p = 5.6 \times 10^{-20}$; $p_{Crawford} = 6.0 \times 10^{-5}$; $p_{Hujoel} = 3.3 \times 10^{-15}$). 877 878 Besides accruing case count from updated hospital records, careful case-control definition 879 and statistical handling of the binary outcomes, probe-level association analysis, and usage 880 of different association models to mimic various dosage mechanisms could explain the 881 increased power of our study. We consequently identified previously unreported CNV-disease 882 associations whose relevance was asserted by follow-up analyses. Only one signal – 17q12

883 CNVs increasing CKD risk – was backed by all approaches, while others were supported by 884 some analysis but not by others -e.g., two associations in the lowest statistical confidence 885 tier were replicated in the EstBB and harbored plausible candidate genes – emphasizing the 886 importance of considering diverse lines of corroborative evidence. Substantial overlap with 887 relevant SNP-GWAS signals and OMIM genes indicates shared genetic mechanisms with 888 convergent effects on the phenotype. Another line of evidence is coincidence with a disease-889 relevant biomarker CNV signals, e.g., four (1q21.1-2, 15q13, 16p12.2, 16p11.2 BP4-5) out of 890 six CNVRs decreasing forced vital capacity [23] were found to increase risk for pulmonary 891 diseases. This demonstrates that biomarkers are efficient proxies underlying (CNV-driven) 892 pathological processes, often increasing the statistical power to detect associations due to 893 their continuous nature. To render binary outcomes continuous, we regressed covariates out 894 of the disease status. With the same goal, more sophisticated approaches have recently been 895 developed that transform binary outcomes in continuous liability scores while borrowing 896 information from age-at-disease onset, sex, and familial history [100]. Successfully applied to 897 SNP-based GWASs, future exploration is warranted to assess their benefit in the context of 898 CNV-GWASs. By coupling a CNV-GWAS framework designed to account for challenges 899 linked to disease CNV association studies in population cohorts to extensive validation, we 900 generated a list of 73 CNV-disease pairs with various levels of supporting evidence that can 901 inform follow-up studies.

902

903 Disease-associated CNVRs harbored genes under stronger evolutionary constraint than 904 those lacking associations and their length correlated with their propensity for pleiotropy, 905 indicating that as previously observed [8], both the number and the nature of genes affected 906 by CNVs influence their pathogenicity. Consequently, large multi-gene recurrent CNVs 907 exhibited the strongest pleiotropy. A longstanding question relates to the identification of 908 causal genes whose altered dosage drives the phenotypic alterations observed in carriers. 909 Models with various levels of complexity have been proposed, ranging from a single driver 910 gene to multiple driver genes modulated by epistatic interactions with other genes in the CNVR

911 [101]. By analyzing disease prevalence in subsets of CNV carriers, association signals could 912 be fine-mapped to narrower regions, pinpointing candidate drivers - such as ABCC6 for kidney 913 stones. In other cases, our data suggests that multiple subregions of the CNVR contribute to 914 increased risk for a given disease by cis-epistasis, as observed for 22g11.2 and ischemic 915 heart disease or 16p13.11 and hypertension. Interestingly, the putative driver for phenotypes 916 originally associated with a CNVR might not be driving our newly identified associations, as 917 shown for the 15q13 CNVR, whose non-neurological phenotypes do not appear to be linked 918 to altered dosage of CHRNA7. Beyond characterizing the pleiotropic pathological 919 consequences of recurrent CNVRs, we demonstrate that dissection of CNV-GWAS signals 920 can fine-map associations and provide mechanistic insights into their phenotypic expression. 921

922 All CNVs increased disease risk and led to an earlier age at onset. Incorporating age at onset 923 information has been shown to improve power to detect associations [100], and more 924 importantly, represents the ultimate proof of clinical relevance. Indeed, many signals mapped 925 to regions whose genetic perturbation has been reported to be pathogenic. These include 926 associations between well-described, clinically relevant gene-disease pairs - such as BRCA1 927 and LDLR deletions increasing the risk for ovarian cancer and IHD, respectively – but for which 928 the role of CNVs in a large population cohort had not been previously investigated. CNVs in 929 these genes have high penetrance but are extremely rare in the UKBB, so that association 930 barely reached GW significance. Follow-up analyses based on the medical records, family 931 history, medication use, and biomarkers could recapitulate additional clinical associations and 932 establish that these deletions were most likely inherited, thereby generating insights into their 933 role in the general population. We further show that many CNVRs previously linked to pediatric 934 genomic disorders also increased risk for a broad spectrum of adult-onset common diseases. 935 These associations were probably overlooked as the medical consequences in adulthood of 936 these etiologies is often poorly characterized owing to ascertainment bias and difficulty to 937 gather large cohorts. While awaiting validation in clinical cohorts of CNV carriers, we hope 938 that these findings will improve clinical characterization of genomic disorders, thereby 939 facilitating diagnosis and allowing physicians to anticipate later-onset comorbidities. For 940 instance, we found carriers of 16p13.11 deletions affecting ABCC6, the causal gene for 941 pseudoxanthoma elasticum, to be at increased risk for kidney stones, paralleling reports from 942 clinical cohorts showing that kidney stones represent an unrecognized feature of the disease 943 [90-92]. Awareness of this disease feature can mitigate kidney stone risk through adapted 944 diet and sufficient water intake. Together, our results advocate for a complex model of variable 945 CNV expressivity and penetrance that can result in a broad range of phenotypes along the 946 rare-to-common disease spectrum and represent fertile ground for in-depth, phenome-wide 947 studies aiming at better characterizing specific CNV regions [38].

948

949 Corroborating the deleterious impact of CNVs on an individual's health parameters, socio-950 economic status, and lifespan [18,22,23,25,31,102–105], we here speculate that it acts by 951 increasing risk for a broad range of common diseases beyond their known role in 952 neuropsychiatric disorders [4-7]. While both duplications and deletions contributed to 953 increased disease risk, the deletion burden's impact was much stronger - especially for 954 metabolic, psychiatric, and musculoskeletal diseases - and for about half the diseases, 955 predominantly driven by deletion of coding region, in line with the commonly accepted view 956 that deletions tend to be more deleterious than duplications and that genetic variation affecting 957 coding regions have stronger phenotypic consequences. Only a marginal fraction of the CNV burden's contribution to disease risk was captured by disease-associated CNVRs and risk for 958 959 four diseases, i.e., hypothyroidism, cataract, arthrosis, and osteoporosis, associated with the 960 burden despite lacking CNV-GWAS signals. With over 10,000 cases, these diseases were not 961 underpowered compared to others, suggesting genuine differences in the genetic architecture, 962 and illustrating the added value of burden tests. Collectively, these results predict that better 963 powered CNV-GWAS are likely to isolate further associations currently captured by the CNV 964 burden.

965

966 A major limitation of our study is the reliance on microarray CNV calls, which allows to assess 967 only a fraction of the CNV landscape, i.e., mostly large CNVs or in regions with high probe 968 coverage. We speculate that small and/or multiallelic CNVs that can only be uncovered by 969 sequencing, will have a genetic architecture closer to the one of SNPs and indels, with higher 970 frequencies and more subtle effect sizes, resembling those of SNPs and indels. These effects, 971 however, are more likely tagged by common variants, limiting novel discoveries. Furthermore, 972 by detecting more events, sequencing-based studies require adapted and more stringent 973 significance thresholds. Still, having improved breakpoint resolution, such CNV calls are also 974 likely to enhance fine-mapping strategies. Microarray CNV calls also exhibit high false positive 975 rates [47]. By using stringent CNV selection criteria, we decrease the latter at the cost of 976 decreasing power to detect true associations. This aspect is particularly relevant given that 977 the type of CNVs we assess are rare and that the UKBB is depleted for disease cases [34], 978 resulting in low powered GWASs. While we adopt strategies to counter the lack of power, our 979 results are likely subject to Winner's curse, only capturing a fraction of the strongest, possibly 980 overestimated effects. This phenomenon might be compensated by UKBB CNV carriers being 981 at the milder end of the clinical spectrum, leading to effect underestimation. An interesting 982 question will be to compare effect sizes from population-based studies to those emerging from 983 clinical cohort. In the future, longitudinal follow-up of UKBB participants will increase the 984 number of cases - especially for late-onset diseases such as Alzheimer's or Parkinson' diseases - allowing better powered CNV-GWASs. Alternatively, meta-analyses can boost 985 986 case number through inclusion of clinical cohorts, at the cost of poorer disease definition due 987 to imperfect data harmonization [8]. Larger and more diverse biobanks linking genotype to 988 phenotype data [106–108] should both validate reported associations and identify new ones.

989

990 CONCLUSIONS

Our study provides in-depth analysis of the role of CNVs in modulating susceptibility to 60common diseases in the general population, broadening our view on how this mutational class

- impacts human health. Besides describing clinically relevant and actionable associations, weillustrate how complex pleiotropic patterns can be dissected to gain new insights into the
- pathological mechanisms of large recurrent CNVs, providing a framework that can be applied
- 996 to an even larger spectrum of diseases.
- 997

998 SUPPLEMENTAL DATA

- 999 Supplemental data include 6 figures, 6 tables, and 3 notes.
- 1000

1001 **DECLARATIONS**

Availability of data and materials: All data used in this study are publicly available, as described in the methods. CNV-GWAS summary statistics (UKBB) will be deposited on the GWAS Catalog upon publication and are available upon request until then.

1005

Competing interests: SO is an employee of MSD at the time of the submission; contribution
to the research occurred during the affiliation at the University of Lausanne.

1008

Funding: The study was funded by the Swiss National Science Foundation (31003A_182632,
AR; 310030_189147, ZK), Horizon2020 Twinning projects (ePerMed 692145, AR), the
Estonian Research Council (PRG687, MJ and RM), and the Department of Computational
Biology (ZK) and the Center for Integrative Genomics (AR) from the University of Lausanne.

Author's contributions: CA, AR and ZK conceived the study; CA carried out the analyses with contributions from MCS, NT, and CJC; The Estonian Biobank Research Team coordinated genotyping and sequencing data acquisition in the EstBB; MJ performed the replication study in the EstBB under the supervision of RM; ZK supervised statistical analyses; SO provided guidance for time-to-event analysis; CA drafted the manuscript and generated

- 1019 the figures; AR and ZK made critical revisions; All authors read, approved, and provided
- 1020 feedback on the final manuscript.
- 1021
- 1022 Acknowledgments: We thank all biobank participants for sharing their data. UKBB and
- 1023 EstBB computations were performed on the JURA server (University of Lausanne) and the
- 1024 High-Performance Computing Center (University of Tartu), respectively.

REFERENCES

- Sudmant PH, Rausch T, Gardner EJ, Handsaker RE, Abyzov A, Huddleston J, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526:75–81.
- 2. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464:704–12.
- 3. Zhang F, Gu W, Hurles ME, Lupski JR. Copy Number Variationin Human Health, Disease, and Evolution. Annu
 Rev Genomics Hum Genet. 2009;10:451–81.
- 4. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-martin C, Walsh T, et al. Strong Association of De Novo Copy
 Number Mutations with Autism. Science (1979). 2007;316:445–9.
- 5. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (1979). 2008;320:539–43.
- 1035
 6. Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, Baker C, et al. Genome-Wide Copy Number
 1036
 1037
 6. Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, Baker C, et al. Genome-Wide Copy Number
 1036
 1037
 1037
- 1038
 7. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. A copy number variation morbidity map of developmental delay. Nat Genet. 2011;43:838–46.
- 1040
 8. Collins RL, Glessner JT, Porcu E, Lepamets M, Brandon R, Lauricella C, et al. A cross-disorder dosage sensitivity map of the human genome. Cell. 2022;185:3041-3055.e25.
- 9. Firth H V., Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: Database of Chromosomal
 Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet. 2009;84:524–33.
- 1044 10. Carvalho CMB, Lupski JR. Mechanisms underlying structural variant formation in genomic disorders. Nat Rev
 Genet. 2016;17:224–38.
- 1046 11. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, et al. A structural variation reference for 1047 medical and population genetics. Nature. 2020;581:444–51.
- 1048
 12. Abel HJ, Larson DE, Chiang C, Das I, Kanchi KL, Layer RM, et al. Mapping and characterization of structural variation in 17,795 deeply sequenced human genomes. Nature. 2020;583:83–9.
- 1050
 13. Halvorsen M, Huh R, Oskolkov N, Wen J, Netotea S, Giusti-Rodriguez P, et al. Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia. Nat Commun. 2020;11:1–13.
- 1053 14. Chen L, Abel HJ, Das I, Larson DE, Ganel L, Kanchi KL, et al. Association of structural variation with 1054 cardiometabolic traits in Finns. Am J Hum Genet. 2021;108:583–96.
- 1055
 15. Beyter D, Ingimundardottir H, Oddsson A, Eggertsson HP, Bjornsson E, Jonsson H, et al. Long-read sequencing of 3,622 Icelanders provides insight into the role of structural variants in human diseases and other traits. Nat Genet. 2021;53:779–86.
- 1058 16. Babadi M, Fu JM, Lee SK, Smirnov AN, Gauthier LD, Walker M, et al. GATK-gCNV: A Rare Copy Number
 1059 Variant Discovery Algorithm and Its Application to Exome Sequencing in the UK Biobank. bioRxiv.
 2022;2022.08.25.504851.
- 1061 17. Fitzgerald T, Birney E. CNest: A novel copy number association discovery method uncovers 862 new
 associations from 200,629 whole-exome sequence datasets in the UK Biobank. Cell Genomics.
 2022;2:100167.

- 1064 18. Kendall KM, Rees E, Escott-Price V, Einon M, Thomas R, Hewitt J, et al. Cognitive Performance Among 1065 Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. Biol Psychiatry. 1066 2017;82:103-10.
- 1067 19. Owen D, Bracher-Smith M, Kendall KM, Rees E, Einon M, Escott-Price V, et al. Effects of pathogenic CNVs on 1068 physical traits in participants of the UK Biobank. BMC Genomics. 2018;19:1-9.
- 1069 20. Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardiñas AF, et al. Medical consequences of 1070 pathogenic CNVs in adults: Analysis of the UK Biobank. J Med Genet. 2019;56:131-8.
- 1071 21. Kendall KM, Rees E, Bracher-Smith M, Legge S, Riglin L, Zammit S, et al. Association of Rare Copy Number 1072 Variants with Risk of Depression. JAMA Psychiatry. 2019;76:818-25.
- 1073 22. Macé A, Tuke MA, Deelen P, Kristiansson K, Mattsson H, Nõukas M, et al. CNV-association meta-analysis in 1074 191,161 European adults reveals new loci associated with anthropometric traits. Nat Commun. 2017;8:1–11.
- 1075 23. Auwerx C, Lepamets M, Sadler MC, Patxot M, Stojanov M, Baud D, et al. The individual and global impact of 1076 copy-number variants on complex human traits. Am J Hum Genet. 2022;109:647-68.
- 1077 24. Aguirre M, Rivas MA, Priest J. Phenome-wide Burden of Copy-Number Variation in the UK Biobank. Am J Hum 1078 Genet. 2019;105:373-83.
- 1079 25. Hujoel MLA, Sherman MA, Barton AR, Mukamel RE, Sankaran VG, Terao C, et al. Influences of rare copy-1080 number variation on human complex traits. Cell. 2022;185:4233-4248.e27.
- 1081 26. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of 35 blood and urine 1082 biomarkers in the UK Biobank. Nat Genet. 2021:53:185-94.
- 1083 27. Li YR, Glessner JT, Coe BP, Li J, Mohebnasab M, Chang X, et al. Rare copy number variants in over 100,000 1084 European ancestry subjects reveal multiple disease associations. Nat Commun. 2020;11:1–9.
- 1085 28. Kopal J, Kumar K, Saltoun K, Modenato C, Moreau CA, Martin-Brevet S, et al. Rare CNVs and phenome-wide 1086 profiling highlight brain structural divergence and phenotypical convergence. Nat Hum Behav. 2023;
- 1087 29. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep 1088 phenotyping and genomic data. Nature. 2018;562:203-9.
- 1089 30. Wright CF, West B, Tuke M, Jones SE, Patel K, Laver TW, et al. Assessing the Pathogenicity, Penetrance, and 1090 Expressivity of Putative Disease-Causing Variants in a Population Setting. Am J Hum Genet. 2019;104:275-1091 86.
- 1092 31. Kingdom R, Tuke M, Wood A, Beaumont RN, Frayling TM, Weedon MN, et al. Rare genetic variants in genes 1093 and loci linked to dominant monogenic developmental disorders cause milder related phenotypes in the general 1094 population. Am J Hum Genet. 2022;109:1308-16.
- 1095 32. Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, et al. Analysis of 589,306 genomes identifies 1096 individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol. 2016;34:531-8.
- 1097 33. Goodrich JK, Singer-Berk M, Son R, Sveden A, Wood J, England E, et al. Determinants of penetrance and 1098 variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nat Commun. 2021;12:1–15.
- 1099 34. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic 1100 and Health-Related Characteristics of UK Biobank Participants with Those of the General Population. Am J 1101 Epidemiol. 2017;186:1026-34.
- 1102 35. Falconer D. The inheritance of liability to certain diseases, estimated from the incidence among relatives. Ann 1103 Hum Genet. 1965;29:51-76.
- 1104 36. Senn StephenS. Statistical issues in drug development. Wiley; 2021.
- 1105 37. Mollon J, Schultz LM, Huguet G, Knowles EEM, Mathias SR, Rodrigue A, et al. Impact of Copy Number Variants 1106 and Polygenic Risk Scores on Psychopathology in the UK Biobank. Biol Psychiatry. 2023;
- 1107 38. Zamariolli M, Auwerx C, Sadler MC, Graaf A Van Der, Lepik K, Schoeler T, et al. The impact of 22g11 . 2 copy-1108 number variants on human traits in the general population. Am J Hum Genet. 2023;110:1-14.
- 1109 39. Giannuzzi G, Schmidt PJ, Porcu E, Willemin G, Munson KM, Nuttle X, et al. The Human-Specific BOLA2 1110 Duplication Modifies Iron Homeostasis and Anemia Predisposition in Chromosome 16p11.2 Autism Individuals. 1111 Am J Hum Genet. 2019;105:947-58.
- 1112 40. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, et al. Cohort profile: Estonian biobank of 1113 the Estonian genome center, university of Tartu. Int J Epidemiol. 2015;44:1137-47.
- 1114 41. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-CM Codes to 1115 Phecodes: Workflow Development and Initial Evaluation. JMIR Med Inform. 2019;7:e14325.
- 1116 42. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, et al. The NHGRI-EBI GWAS Catalog: knowledgebase 1117 and deposition resource. Nucleic Acids Res. 2023;51:D977-85.
- 1118 43. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), 1119 a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005;33.
- 1120 44. Karczewski KJ., Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint 1121 spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434-43.

- 1122 45. Aguet F, Barbeira A, Bonazzola R, Brown A, Castel S, Jo B, et al. The GTEx Consortium atlas of genetic 1123 regulatory effects across human tissues. Science (1979). 2020;369:1318-30.
- 1124 46. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. PennCNV: An integrated hidden Markov model 1125 designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome 1126 Res. 2007;17:1665-74.
- 1127 47. Macé A, Tuke MA, Beckmann JS, Lin L, Jacquemont S, Weedon MN, et al. New quality measure for SNP array 1128 based CNV detection. Bioinformatics. 2016;32:3298-305.
- 1129 48. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the 1130 challenge of larger and richer datasets. Gigascience. 2015;4:1-16.
- 1131 49. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput 1132 sequencing data. Nucleic Acids Res. 2010;38:e164-e164.
- 1133 50. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at 1134 UCSC. Genome Res. 2002;12:996-1006.
- 1135 51. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using 1136 correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361-9.
- 1137 52. Therneau TM. Survival Analysis [R package survival version 3.5-3]. 2022 [cited 2023 Apr 17]; Available from: 1138 https://CRAN.R-project.org/package=survival
- 1139 53. Berman JJ. Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases. 1140 Elsevier Inc.: 2014.
- 1141 54. Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, et al. Bietti Crystalline Corneoretinal Dystrophy Is 1142 Caused by Mutations in the Novel Gene CYP4V2. Am J Hum Genet. 2004;74:817-26.
- 1143 55. Zhou W, Otto EA, Cluckey A, Airik R, Hurd TW, Chaki M, et al. FAN1 mutations cause karyomegalic interstitial 1144 nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012;44:910-5.
- 1145 56. Kryger MH, Roth T, Goldstein CA. Principles and Practice of Sleep Medicine. Elsevier Health Sciences; 2021.
- 1146 57. Shinawi M, Liu P, Kang SHL, Shen J, Belmont JW, Scott DA, et al. Recurrent reciprocal 16p11.2 1147 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, 1148 and abnormal head size. J Med Genet. 2010;47:332-41.
- 1149 58. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between Microdeletion and 1150 Microduplication at 16p11.2 and Autism. N Engl J Med. 2008;358:667-75.
- 1151 59. D'Angelo D, Lebon S, Chen Q, Martin-Brevet S, Snyder LAG, Hippolyte L, et al. Defining the Effect of the 1152 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities. JAMA Psychiatry. 2016;73:20–30.
- 1153 60. Reinthaler EM, Lal D, Lebon S, Hildebrand MS, Dahl HHM, Regan BM, et al. 16p11.2 600 kb Duplications 1154 confer risk for typical and atypical Rolandic epilepsy. Hum Mol Genet. 2014;23:6069-80.
- 1155 61. Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z, et al. Mirror extreme BMI 1156 phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature. 2011;478:97–102.
- 1157 62. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, et al. Microduplications of 16p11.2 are 1158 associated with schizophrenia. Nat Genet. 2009;41:1223-7.
- 1159 63. Walters RG, Jacquemont S, Valsesia A, De Smith AJ, Martinet D, Andersson J, et al. A new highly penetrant 1160 form of obesity due to deletions on chromosome 16p11.2. Nature. 2010;463:671-5.
- 1161 64. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the 1162 breast and ovarian cancer susceptibility gene BRCA1. Science (1979). 1994;266:66-71.
- 1163 65. Iacocca MA, Hegele RA. Role of DNA copy number variation in dyslipidemias. Curr Opin Lipidol. 2018;29:125-1164 32.
- 1165 66. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: 1166 mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133-70.
- 1167 67. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial 1168 hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093.
- 1169 68. lacocca MA, Wang J, Dron JS, Robinson JF, McIntyre AD, Cao H, et al. Use of next-generation sequencing to 1170 detect LDLR gene copy number variation in familial hypercholesterolemia. J Lipid Res. 2017;58:2202-9.
- 1171 69. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for 1172 the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the 1173 management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis 1174 Society (EAS). Eur Heart J. 2020;41:111-88.
- 1175 70. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney 1176 function from analyses of a million individuals. Nat Genet. 2019;51:957-72.
- 1177 71. Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, et al. Discovery and prioritization of variants 1178 and genes for kidney function in >1.2 million individuals. Nat Commun. 2021;12:1-17.

- 1179 72. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset 1180 diabetes of the young. N Engl J Med. 2001;345:97180.
- 1181 73. Mefford HC, Clauin S, Sharp AJ, Moller RS, Ullmann R, Kapur R, et al. Recurrent Reciprocal Genomic 1182 Rearrangements of 17q12 Are Associated with Renal Disease, Diabetes, and Epilepsy. Am J Hum Genet. 1183 2007;81:1057-69.
- 1184 74. Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, Itsara A, et al. A recurrent 16p12.1 1185 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42:203-9.
- 1186 75. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S, et al. CNVs 1187 conferring risk of autism or schizophrenia affect cognition in controls. Nature. 2013;505:361-6.
- 1188 76. Girirajan S, Pizzo L, Moeschler J, Rosenfeld J. 16p12.2 Recurrent Deletion. GeneReviews® [Internet]. 2018 1189 [cited 2023 Apr 4]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK274565/
- 1190 77. Stevelink R, Campbell C, Chen S, The International League Against Epilepsy Consortium on Complex 1191 Epilepsies. Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-1192 specific genetic architecture. medRxiv. 2022;2022.06.08.22276120.
- 1193 78. Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, et al. Genetic variants of calcium and 1194 vitamin D metabolism in kidney stone disease. Nat Commun. 2019;10:1-10.
- 1195 79. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 1196 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412-25.
- 1197 80. De Kovel CGF. Trucks H. Helbig I. Mefford HC, Baker C, Leu C, et al. Recurrent microdeletions at 15g11.2 and 1198 16p13.11 predispose to idiopathic generalized epilepsies. Brain. 2010;133:23-32.
- 1199 81. Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, et al. Rare Deletions at 16p13.11 1200 Predispose to a Diverse Spectrum of Sporadic Epilepsy Syndromes. Am J Hum Genet. 2010;86:707–18.
- 1201 82. Alkuraya FS, Cai X, Emery C, Mochida GH, Al-Dosari MS, Felie JM, et al. Human Mutations in NDE1 Cause 1202 Extreme Microcephaly with Lissencephaly. Am J Hum Genet. 2011;88:536-47.
- 1203 83. Bakircioglu M, Carvalho OP, Khurshid M, Cox JJ, Tuysuz B, Barak T, et al. The Essential Role of Centrosomal 1204 NDE1 in Human Cerebral Cortex Neurogenesis. Am J Hum Genet. 2011;88:523-35.
- 1205 84. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: Mutations in the MRP6 gene 1206 encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A. 2000;97:6001-1207 6.
- 1208 85. Struk B, Cai L, Zäch S, Ji W, Chung J, Lumsden A, et al. Mutations of the gene encoding the transmembrane 1209 transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med. 2000;78:282-6.
- 1210 86. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, et al. Mutations in a gene encoding an 1211 ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000;25:223-7.
- 1212 87. Bergen AAB, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, et al. Mutations in ABCC6 cause 1213 pseudoxanthoma elasticum. Nat Genet. 2000;25:228-31.
- 1214 88. Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, Goöring HHH, et al. A Spectrum of ABCC6 Mutations 1215 Is Responsible for Pseudoxanthoma Elasticum. Am J Hum Genet. 2001;69:749-64.
- 1216 89. Ringpfeil F, Nakano A, Uitto J, Pulkkinen L. Compound Heterozygosity for a Recurrent 16.5-kb Alu-Mediated 1217 Deletion Mutation and Single-Base-Pair Substitutions in the ABCC6 Gene Results in Pseudoxanthoma 1218 Elasticum. Am J Hum Genet. 2001;68:642-52.
- 1219 90. Ralph D, Allawh R, Terry IF, Terry SF, Uitto J, Li QL. Kidney Stones Are Prevalent in Individuals with 1220 Pseudoxanthoma Elasticum, a Genetic Ectopic Mineralization Disorder. Int J Dermatol Venereol. 2020;3:198-1221 204
- 1222 91. Legrand A, Cornez L, Samkari W, Mazzella JM, Venisse A, Boccio V, et al. Mutation spectrum in the ABCC6 1223 gene and genotype-phenotype correlations in a French cohort with pseudoxanthoma elasticum. Genetics in 1224 Medicine. 2017;19:909-17.
- 1225 92. Letavernier E, Kauffenstein G, Huguet L, Navasiolava N, Bouderlique E, Tang E, et al. ABCC6 deficiency 1226 promotes development of randall plaque. Journal of the American Society of Nephrology. 2018;29:2337-47.
- 1227 93. Nitschke Y, Baujat G, Botschen U, Wittkampf T, Du Moulin M, Stella J, et al. Generalized Arterial Calcification 1228 of Infancy and Pseudoxanthoma Elasticum Can Be Caused by Mutations in Either ENPP1 or ABCC6. Am J 1229 Hum Genet. 2012;90:25-39.
- 1230 94. Le Boulanger G, Labrèze C, Croué A, Schurgers LJ, Chassaing N, Wittkampf T, et al. An unusual severe 1231 vascular case of pseudoxanthoma elasticum presenting as generalized arterial calcification of infancy. Am J 1232 Med Genet A. 2010;152A:118-23.
- 1233 95. McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JAS, et al. 22q11.2 deletion 1234 syndrome. Nat Rev Dis Primers. 2015;1:1-19.
- 1235 96. Bartik LE, Hughes SS, Tracy M, Feldt MM, Zhang L, Arganbright J, et al. 22q11.2 duplications: Expanding the 1236 clinical presentation. Am J Med Genet A. 2022;188:779-87.

- 1237 97. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, Stevenson RE, et al. A recurrent 15q13.3 microdeletion 1238 syndrome associated with mental retardation and seizures. Nat Genet. 2008;40:322-8.
- 1239 98. Lowther C, Costain G, Stavropoulos DJ, Melvin R, Silversides CK, Andrade DM, et al. Delineating the 15q13.3 1240 microdeletion phenotype: a case series and comprehensive review of the literature. Genetics in Medicine. 1241 2015;17:149-57.
- 1242 99. Gillentine MA, Schaaf CP. The Human Clinical Phenotypes of Altered CHRNA7 Copy Number. Biochem 1243 Pharmacol. 2015;97:352.
- 1244 100. Pedersen EM, Agerbo E, Plana-Ripoll O, Grove J, Dreier JW, Musliner KL, et al. Accounting for age of onset 1245 and family history improves power in genome-wide association studies. Am J Hum Genet. 2022;109:417-32.
- 1246 101. Golzio C, Katsanis N. Genetic architecture of reciprocal CNVs. Curr Opin Genet Dev. 2013;23:240-8.
- 1247 102. Männik K, Mägi R, Macé A, Cole B, Guyatt AL, Shihab HA, et al. Copy number variations and cognitive 1248 phenotypes in unselected populations. JAMA. 2015;313:2044-54.
- 1249 103. Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, et al. Genome-wide SNP and CNV 1250 analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet. 1251 2013;45:513-7.
- 1252 104. Dauber A, Yu Y, Turchin MC, Chiang CW, Meng YA, Demerath EW, et al. Genome-wide association of copy-1253 number variation reveals an association between short stature and the presence of low-frequency genomic 1254 deletions. Am J Hum Genet. 2011;89:751-9.
- 1255 105. Saarentaus EC. Havulinna AS. Mars N. Ahola-Olli A. Kiiskinen TTJ. Partanen J. et al. Polygenic burden has 1256 broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number 1257 variants. Mol Psychiatry. 2021;26:4884-95.
- 1258 106. Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, et al. The 'All of Us' Research 1259 Program. N Engl J Med. 2019;381:668-76.
- 1260 107. Hunter-Zinck H, Shi Y, Li M, Gorman BR, Ji SG, Sun N, et al. Genotyping Array Design and Data Quality 1261 Control in the Million Veteran Program. Am J Hum Genet. 2020;106:535-48.
- 1262 108. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights 1263 from a well-phenotyped isolated population. Nature. 2023;613:508-18.